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SUMMARY 
 
The control of gene expression is a fundamental process to bring the ge-
nome to life, and it pervades most of biology, from cell proliferation and dif-
ferentiation to development. It is well recognized that gene expression is 
regulated at several levels. Cells need to integrate intrinsic and environ-
mental information and coordinate multiple regulatory mechanisms of gene 
expression to properly exert biological functions.   
Mis-regulation of gene expression at any level can lead to disease. The 
various steps in the pathway from DNA sequence to proteins seem to be 
connected and coordinated with each other. Post-transcriptional control is 
mediated by various combinations of RNA-binding proteins (RBPs) that de-
termine the fate of the tagged transcripts and that seem to regulate specific 
subsets of mRNAs.  
Small interfering RNAs and microRNAs, together with protein effector 
complexes, can also control the degradation and translation of target tran-
scripts;  
MicroRNAs (miRNAs) are single-stranded RNAs (ssRNAs) of 19–25 nu-
cleotides in length that are generated from endogenous hairpin-shaped 
transcripts1 and they function as guide molecules in post-transcriptional 
gene silencing by base pairing with target mRNAs, which leads to mRNA 
cleavage or translational repression.  There is a growing number of reports 
that link miRNAs to the regulation of pathways associated with human dis-
eases such as cancer, neurological diseases and most recently also with viral 
and metabolic diseases.  
Modified synthetic anti-miRNA oligonucleotides (AMOs) are useful tools 
in specifically inhibiting individual miRNAs, thereby helping to unravel the 
function of miRNAs and their targets. Similar to antisense-based oligonu-
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cleotides (ASOs), AMOs may contribute to the prioritization of pharmaceuti-
cal targets and have the potential to eventually progress into a new class of 
therapeutic agents. Among these, the peptide nucleic acids (PNAs) show a 
great potential as therapeutic and diagnostic reagents, due to their higher af-
finity and specificity for complementary nucleobase sequences and to their 
higher resistance to enzymatic degradation than the corresponding natural 
nucleic acids.  
PNAs are compounds that are analogous to oligonucleotides, but differ in 
composition. In PNAs, in fact, the deoxyribose backbone of oligonucleotide is 
replaced by subunits of peptide backbone, constituted by repeating units of 
N-(2- aminoethyl)glycine and attached to a nucleobase through a methylene 
carbonyl linker. As PNAs bind selectively and effectively to both DNA and 
RNA, they can target mRNA, miRNA or DNA, interfering  in transcription and 
translation. 
In this work PNA based molecules designed to interfere in the maturation 
of miRNA and gene expression were obtained. 
To achieve these goals,  firstly a new, efficient and inexpensive protocol to 
obtain PNA by Fmoc solid-phase synthesis was developed.  
The new protocol involves the PNA monomer activation with HOBt and 
HBTU in place of  HATU, a more expensive activators, and NMM in pyridine 
as a base, in place of DIPEA and Lutidine (standard bases). Furthermore a 
comparison between standard and new protocol revealed that yields using 
the new coupling conditions  were significantly improved.   
To interfere in the miRNA function PNA anti-premiR were obtained.  PNA 
sequences targeting  the "sense region" (PNA 5) and the " 5’ end region" 
(PNA 6) of the pre-miR210 were designed. 
To improve PNA delivery in cells, conjugation to cell-penetrating pep-
tides, such as Tat peptide, and nuclear localization signal (NLS and biNLS) 
peptides was carried out. Furthermore, in order to demonstrate that the de-
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signed PNAs were able to bind to the pre-miRNA210  a Thiazole Orange 
(TO) modified PNA for fluorescence studies was obtained. Finally, with the 
aim to verify whether these molecules were capable of entering the cells 
some FITC modified PNAs for FACS experiments were synthesized too.  
Fluorescence studies  indicated that PNA 5 is able to hybridize efficiently 
with target RNA sequences, but FACS experiments revealed in a qualitative 
manner that a low cellular uptake limits the potentialities of  designed oli-
gomers.  
A further aim of this project was the synthesis and the characterization of 
new  modified PNA monomers. Several PNA analogues with modification on 
the backbone and bases have been obtained so far in the attempt to over-
come solubility, uptake and aggregation issues and a recently investigated 
family of PNA analogues is represented by gamma Peptide Nucleic Acid 
(PNA), PNA derivatives bearing a substituent, usually corresponding to the 
side chain of a natural amino acid, in the gamma position of the backbone.  
Several analogues have been explored so far, having methyl, hydroxy-
methyl, thiomethyl, aminobutyl and guanidinium groups attached and stud-
ies showed that the introduction in gamma position of a functional group 
leads to an improvement of  PNA oligomer features, such as a high pre-
structural organization as well as a better ability to invade a mixed sequence 
DNA double helix.  
In this work  sulphate PNAs were investigated. Protocols for the synthe-
sis of the four PNA monomers having the sulphate group in the gamma posi-
tion of the backbone and of oligomers containing sulphate monomers were 
set up. The conformational preferences of the PNA monomers were investi-
gated by NMR. Studies on the secondary structure of a polypirimidine oli-
gomer were carried out by CD. The ability of the modified oligomer to inter-
act with DNA,  the specificity and affinity of binding were investigated by UV 
and CD.  
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Finally, the ability of the sulphate PNA to interfere with the transcription 
of the ErbB2 gene on a human cell line overexpressing ErbB2 (SKBR3), by 
FACS and qPCR was explored. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
12 
 
CHAPTER 1 
INTRODUCTION 
 
1. GENE REGULATION 
 
Regulation of gene expression is fundamental for the coordinate synthe-
sis, assembly and localization of the macromolecular structures of cells2. 
This is achieved by a multi-step program that is highly interconnected and 
regulated at diverse levels (Figure 1).  
Gene regulation can occur at three possible places in the production of an 
active gene product3. First, the transcription of the gene can be regulated. 
This is known as transcriptional regulation4. When the gene is transcribed 
and how much it is transcribed influences the amount of gene product that is 
produced. Second, if the gene encodes a protein, it can be regulated at the 
translational level. This is known as translational regulation. How often 
the mRNA is translated influences the amount of gene product that is ob-
tained. Third, gene products can be regulated after they are completely syn-
thesized by either post-transcriptional or post-translational regulation 
mechanisms5. Both RNA and protein can be regulated by degradation to con-
trol how much active gene product is present6. Both can also be subjected to 
modifications such as the methylation of nucleosides in rRNA, the extensive 
modifications made to tRNAs (over 80 modified nucleosides have been de-
scribed), or the phosphorylation of response-regulator proteins7.  
These modifications can play a major role in the function of the gene 
product. In general, every step that is required to make an active gene prod-
uct can be the focus of a regulatory event. In practice, most bacterial regula-
tion occurs at the transcriptional level. Transcriptional regulation is thought 
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to be more frequent because it would be a waste to make the RNA if neither 
the RNA nor its encoded protein is needed. 
Gene regulation starts in the nucleus, where transcription factors bind to 
specific DNA sequences proximal to the genes they regulate and recruit RNA 
polymerases for RNA synthesis.  As soon as RNA precursors are formed, they 
get covered by a host of proteins forming ribonucleoprotein complexes8. 
Messenger RNA-binding proteins (mRBPs) associate with nascent mRNA 
precursors and mediate diverse RNA processing reactions including end 
capping, splicing, editing, end cleavage and polyadenylation.  The transcripts 
are subsequently exported through nuclear pores to the cytoplasm where 
they may undergo localization to subcellular regions by complexes consist-
ing of motor proteins and RBPs or by the signal recognition particle9.  
The transcripts assemble with translation factors and ribosomes for pro-
tein synthesis, which is controlled by global or transcript-specific mecha-
nisms10. 
 
 
 
Figure 1: Gene expression is controlled at multiple steps: Transcriptional control (DNA 
binding proteins); Post-Transcriptional control (RNA binding proteins); Post-
Translational control; 
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Finally, mRNAs undergo exonuclease-mediated degradation by diverse 
decay pathways11. The fate and location of proteins can be further controlled 
through modification of specific amino acids, cleavage by site-specific prote-
ases and degradation through the proteasome.  The majority of studies to 
date have focused on transcriptional control mechanisms, but the impor-
tance of post-transcriptional mechanisms in regulating gene expression in 
eukaryotes is becoming increasingly clear. 
Post-transcriptional regulation of gene expression plays important roles 
in diverse cellular processes such as development, metabolism and cancer 
progression6. Whereas many classical studies explored the mechanistics and 
physiological impact on specific mRNA substrates, the recent development 
of genome-wide analysis tools enables the study of post-transcriptional gene 
regulation on a global scale. Importantly, these studies revealed distinct 
programs of RNA regulation, suggesting a complex and versatile post-
transcriptional regulatory network12. This network is controlled by specific 
RNA-binding proteins and/or non-coding RNAs, which bind to specific se-
quence or structural elements in the RNAs and thereby regulate subsets of 
mRNAs that partly encode functionally related proteins. 
Over the past decade, small RNAs emerged as a new class of key regula-
tors of eukaryotic biology, helping to control cellular metabolism, growth 
and differentiation, to maintain genome integrity and to combat viruses and 
mobile genetic elements13. 
This diverse class of RNAs includes small interfering RNAs (siRNAs), mi-
croRNA (miRNAs) and PIWI-interacting RNAs (piRNAs)14, all of which asso-
ciate with multiple protein components within a complex to regulate par-
tially or perfectly complementary transcripts15. The common feature of RNAi 
and all related small-RNA-mediated silencing pathways is the association of 
a small silencing RNA (also known as a guide RNA in this context) with a 
protein of the Argonaute family. The resultant protein–RNA complex forms 
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the minimal core of the effector complex known as the RISC. Within the 
RISC, the small RNA functions as a sequence-specific guide that recruits an 
Argonaute protein to complementary target transcripts through base-
pairing interactions16. The target transcripts, typically mRNAs, are then ei-
ther cleaved or prevented from being translated by ribosomes, leading to 
their degradation. Throughout evolution, the Argonaute family has diverged 
into specialized clades (or subfamilies) that recognize different small RNA 
types and confer the specific effects of the various small-RNA silencing 
pathways. 
Both siRNAs and miRNAs associate with members of the AGO clade of Ar-
gonaute proteins, whereas piRNAs bind to those of the PIWI clade. In classic 
RNAi, which is elicited by siRNAs, Argonaute proteins silence targeted 
mRNAs by catalysing their endo nucleolytic cleavage, a process known as 
slicing. The PIWI clade of the Argonaute protein family is thought to use slic-
ing in piRNA-mediated silencing of mobile genetic elements in the germ 
line17 (Figure 2). 
 
 
 
Figure 2. Double-stranded RNA (siRNA) entering the Argonaute Complex. 
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To function as an effector of small-RNA-mediated silencing, the Argonaute 
protein must bind to the guide RNA strand, eject the non-guide (passenger) 
strand of the siRNA or miRNA–miRNA* duplex (where miRNA* is the pas-
senger strand) during loading, and subsequently recognize the target RNA. 
 
 
1.1. MICRORNAS   
 
MicroRNAs  are a class of 20-25 nucleotide-long non coding RNAs that 
modulate gene expression through canonical base pairing between the seed 
sequence of miRNA ( nucleotides 2-8- at its 5’ end) and its complementary 
seed match sequence (which is present in the 3’ UTR of target mRNAs)18. 
miRNAs have a peculiar biogenesis: First, they are transcribed as primary  
(pri-miRNAs) by RNA polymerase II. Each pri-miRNA contains one or more 
hairpin structures that is recognized and processed by the microprocessor 
complex, which consists of the RNase III type endonuclease Drosha and its 
partner, DGCR8 (Figure 3) . 
The microprocessor complex generates a 70-nucleotide stem loop known 
as the precursor miRNA (pre-miRNA), which is actively exported to the cy-
toplasm by exportin 5. In the cytoplasm, the pre-miRNA is recognized by 
Dicer, another RNase III type endonuclease, and TAR RNA-binding protein 
(TRBP; also known as TARBP2). Dicer cleaves this precursor, generating a 
20-nucleotide mature miRNA duplex19. Generally, only one strand is selected 
as the biologically active mature miRNA and the other strand is degraded. 
The mature miRNA is loaded into the RNA-induced silencing complex 
(RISC), which contains Argonaute (Ago) proteins and the single-stranded 
miRNA20. 
Mature miRNA allows the RISC to recognize target mRNAs through partial 
sequence complementarity with its target. In particular, perfect base pairing 
17 
 
between the seed sequence of the miRNA (from the second to the eighth nu-
cleotide) and the seed match sequences in the mRNA 3′ UTR is crucial21. 
 
 
Figure 3: miRNAs biogenesis and mechanisms of action 
 
The RISC can inhibit the expression of the target mRNA through two main 
mechanisms that have several variations: removal of the polyA tail (deade-
nylation) by fostering the activity of deadenylases (such as CCR4–NOT), fol-
lowed by mRNA degradation and blockade of translation at the initiation 
step or at the elongation; 
Therefore RISCs use the small RNAs as guides for the sequence-specific si-
lencing of messenger RNAs that contain complementary sequence through 
inducing the degradation of the mRNAs or repressing their translation. In 
addition, in certain organisms, a specialized nuclear Argonaute-containing 
complex, known as the RNA-induced transcriptional silencing complex 
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(RITS), mediates transcriptional gene silencing by inducing heterochromatin 
formation14. 
The first glimpse into the new world of small RNAs came with seminal 
papers from Ambros, Ruvkun and colleagues: they reported that lin-4 and 
let-7, the first miRNA genes identified, control developmental timing in 
nematodes by modulating the expression of other genes at the post-
transcriptional level22.  
The first discovery providing evidence that gene regulation mediated by 
small RNAs of 22-nt may exist in species beyond worms came from Pas-
quinelli et al.23. They found that let-7 RNA expression can be detected in a 
wide range of animal species, including vertebrate, ascidians, hemichordate, 
mollusc, annelid and arthropod. Other 3 members of the  let-7 family were 
identified in C. elegans and at least 15 in human, but only one in Droso-
phila24. This extensive conservation strongly indicated a more general role 
of small RNAs in developmental regulation, as supported by the recent char-
acterization of miRNA functions in metazoan organisms.  
The second discovery, suggesting the widespread existence of miRNAs 
was the finding that small interfering RNAs of about 22nt lenght (siRNAs) 
are central to RNA interference (RNAi)25. 
Generally, each miRNA is thought to regulate multiple genes, hundreds of 
miRNA genes were predicted (Lim et al. 2003b) and several hundreds have 
been already cloned and sequenced from C.elegans, Drosophila, Arabidopsis, 
mice and human26. The large number of miRNAs and homologous sequences 
of many miRNAs among organisms suggest that these RNAs might constitute 
an abundant and conserved component of the gene regulatory machinery27.  
Several studies have indicated that the 5' end of the miRNA is crucial for the 
stability and proper loading of the miRNA into the miRISC complex, and this 
end is also important for biological function. 
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Recent studies have revealed that miRNAs have key roles in diverse regu-
latory pathways, including control of developmental timing, haematopoietic 
cell differentiation, apoptosis, cell proliferation and organ development28.  
MicroiRNAs and their targets seem to form complex regulatory networks. 
For example, a single miRNA can bind to and regulate many different mRNA 
targets and, conversely, several different miRNAs can bind to and coopera-
tively control a single mRNA target. 
Recent work by the Bartel and Burge laboratories predicted that over one 
third of all human genes are targeted by miRNAs. 
Consequently, the unique combination of miRNAs that are expressed in 
each cell type might affect or ‘dampen’ the utilization of thousands of 
mRNAs1. 
Because miRNAs potentially have a broad influence over several diverse ge-
netic pathways, the deletion or misexpression of these small RNAs is likely 
to be pleotropic and contribute to disease, including cancer. 
They function as post-transcriptional repressors of their target genes 
when bound to the specific sites in the 3′ untranslated region (UTR) of the 
target mRNA29. To date, only a small number of miRNAs are known for their 
biological functions. For example, bantam RNA from Drosophila 
melanogaster suppresses apoptosis and stimulates cell proliferation. Being 
expressed in a temporal and tissue-specific manner, bantam RNA regulates 
tissue formation during development. Another nematode miRNA, lsy-6RNA, 
was identified in a genetic screen for left–right asymmetry of neuronal 
chemoreceptor expression. Lsy-6RNA targets cog-1, which encodes a tran-
scription factor30.  
In mammals, miR-181 is involved in the control of haematopoiesis 
through as-yet-unknown targets. More recently, miR-196 miRNAs were 
shown to repress the expression of the HoxB8, which encodes a transcrip-
tion factor that is important in developmental regulation31; miR-196 family 
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RNAs are the first examples of animal miRNAs that cause target mRNA 
cleavage rather than translational repression (Table 1). 
 
 
miRNA Function Known targets Species 
Lin-4 Developmental timing lin-14, lin-28 Ce 
Let-7 Developmental timing lin-41, hbl-1 Ce 
Lsy-6 Neuronal patterning cog-1 Ce 
miR-273 Neuronal patterning die-1 Ce 
bantam 
Cell death, 
 proliferation 
hid Dm 
miR-14 Cell death, fat storage Caspase? Dm 
miR-181 Haematopoiesis ? Mm 
miR-196 Devevelopment 
HoxB8, HoxC8, 
HoxD8, HoxA7 
Mm 
miR-143 
Adipocyte differentia-
tion 
? Hs 
miR-375 Insulin secretation Myotrophin Mm 
Table 1: microRNAs functions 
 
Another D. melanogaster miRNA, miR-14, is a strong suppressor of apop-
tosis32. In addition, miR-14 also seems to have unrelated functions in the D. 
melanogaster stress-response pathway and in regulating fat metabolism. 
Other characterized miRNAs have essential functions during development 
and direct the proper differentiation of cells into various tissues. Examples 
include miR-273, which is involved in patterning the C. elegans nervous sys-
tem33; miR-430 in Danio rerio brain development; miR-375 in mammalian 
pancreatic islet-cell development and the regulation of insulin secretion34; 
miR-143 during mammalian adipocyte differentiation35; miR-196 in mam-
malian limb patterning36; and the miR-1 genes during mammalian heart de-
velopment37. 
In small-sized viral genomes, miRNAs offer an efficient means to specifi-
cally inactivate host cell defense factors compared to virally encoded pro-
teins. Several recent reports describe miRNAs cloned from a variety of vi-
ruses such as herpes viruses and human immunodeficiency virus 1 (HIV-
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1)38. Pfeffer et al. identified five miRNAs in Epstein-Barr virus (EBV) and 
nine miRNAs encoded by human cytomegalovirus (HCMV)39, while, simulta-
neously, Cai et al. found eleven miRNAs from Kaposi’s sarcoma-associated 
virus (KSHV)40. Finally, recent evidence indicates that miRNAs might also 
function as tumour suppressors and oncogenes (Figure 4). 
 
 
Figure 4: MicroRNAs can function as tumour suppressors or oncogenes. 
 
The first indication that miRNAs could function as tumour suppressors 
came from a report by Calin et al. that showed that patients who were diag-
nosed with a common form of adult leukaemia, B-cell chronic lymphocytic 
leukemia (CLL), often have deletions or downregulation of two clustered 
miRNA genes, mir-15a and mir-16-141. A recent report by Cimmino et al. 
showed that miR-15a and miR-16-1 negatively regulate BCL2, which is an 
anti-apoptotic gene that is often overexpressed in many types of human can-
cers, including leukaemias and lymphomas42.  
Therefore, it is thought that the deletion or downregulation of mir-15a 
and mir-16-1 results in increased expression of BCL2, promoting leu-
kaemogeneis and lymphomagenesis in haematopoietic cells. 
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Additional studies have shown a strong correlation between abrogated ex-
pression of miRNAs and oncogenesis. For example, mature miRNA levels of 
miR-143 and miR-145 are significantly reduced in colorectal tumours43. An-
other report demonstrated that miR-21 is upregulated in glioblastoma (Ta-
ble 2). 
 
miRNA Gene loci Cancer association Function 
miR-15a, miR-16-1 Chromosome 13q14 Frequently deleted or 
downregulatedin B-cell 
chronic lymphocytic 
leukemia 
TS 
miR-143, miR-145 Chromosome Sq32-33 Dowregulated in breast, 
prostate, cervical and 
lymphoid cancer cell 
lines 
TS 
miR-21 Chromosome 17q23.2 Anti-apoptotic factor: 
upregulated in glioblas-
tomas and breast cancer 
OG 
let-7 family mem-
bers 
Multiple loci Negatively regulate the 
Ras oncogenes 
TS 
miR-142 Chromosome 17q22 Associate to Leukemia N/A 
BIC/miR-155 Chromosome 21q21 Upregulated in breast 
cancer 
OG 
miR-17-19b cluster Chromosome 13q31-32 Found in Hepatocellular 
carcinoma 
TS/OG 
Table 2: MicroRNAs that are associated with human cancers 
  
Therefore, in a global sense, miRNAs might function to drive cells into a 
more differentiated state, and the expression profiles of miRNAs in tumours 
compared with normal tissues might represent the degree of differentiation 
in those cells. These studies implied that abnormalities in miRNA expression 
might directly result in the de-differentiation of cells, allowing tumour for-
mation to occur. 
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1.1.1. ANTAGOMIR 
 
With the identification of a vast number of miRNAs, each carrying a long 
list of putative targets, the challenge is now to understand their biological 
function. Much of the progress in understanding miRNA function to date de-
rives from inhibition studies with antisense oligonucletides (ASOs)44. The 
importance of such reagents also is that microRNA targeting represents a 
novel and undeveloped approach toward potential therapeutic applications. 
Where a deletion or a  mutation is present in the miRNA gene itself, a thera-
peutic approach could entail exogenous delivery of corrective synthetic 
miRNAs in the form of (siRNA-like) dsRNA. This principle was first demon-
strated in vitro by Zeng et al., who showed in a model system that partially 
complementary siRNAs can inhibit target mRNAs by miRNA-like transla-
tional inhibition45. 
Oligonucletides (ON) or analogs that inhibit miRNAs were called an-
tagomir and they function essentially by a steric block, RNase H-
independent  and RISC-independent, antisense mechanism through com-
plementary binding  to the microRNA sequence (Figure 5). 
The cellular outcome of such binding is still unclear, with reports arguing ei-
ther in favor of a mechanism based on simple sequestration by stoichiomet-
ric complex formation between the mature microRNA and the ON inhibi-
tor46, or in favor of a yet unknown mechanism by which complex formation 
leads to degradation of the target microRNA47. The result of these mecha-
nisms is marked by the inhibition of microRNA-mRNA complex and conse-
quently by the interference of the gene transcription process. 
Over the past decade, however, microRNAs inhibition by ON has not proven 
to be a robust or generally reliable technology. In fact, natural oligonucleo-
tides have some unfavorable features: 
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Figure 5: Interference with the miRNA pathway using synthetic oligonucleotides.  Inhibi-
tion of miRNA activity may be achieved by introducing anti-miRNA oligonucleotides 
(AMOs) fully complementary to the pri-miRNA, the pre-miRNA or the mature miRNA. 
 
First of all, as they are, they cannot penetrate spontaneously into the cell (it 
is usually necessary to employ a commercially available cationic lipid or 
other transfection reagent) , and even if they were to succeed, they would be 
immediately subjected to enzymatic cleavage of the endonuclease and ex-
onuclease. 
Furthermore, it has been difficult to identify oligonucleotides that act as 
potent inhibitors of miRNAs in particular and of gene expression in general 
because of the difficulties in predicting the secondary structures of RNA. Due 
to the secondary structures of RNA there is a limited number of freely acces-
sible regions, therefore a high number of oligomers need to be screened to 
identify those (or the one) which efficiently work48. 
For these reasons the need for antisense oligomers that are more potent 
and more selective has been widely recognized and has led to the develop-
ment of chemical modifications to improve binding and selectivity (Figure 
6). 
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Figure 6: Nucleic acid analogues (phosphorothioate DNA, 2’-O-methoxy-ethyl RNA, mor-
pholino, PNA and LNA). 
 
 
The introduction of phosphorothioate linkages (PS), for example,  pro-
foundly influences the proprieties of antisense oligonucleotides. PS linkage 
not only enhance the nuclease resistance but also improve pharmacokinetic 
properties by promoting binding to serum proteins, greatly increasing in 
vivo half-life, thereby facilitating the development of oligonucleotide 
drugs49. Another strategy for improving the efficiency of antisense oligonu-
cleotides is to increase the difference between their affinity for their in-
tended targets and their propensity to bind to nontargeted molecules. 
The 2’-O-methyl-group (OMe) is one of the oldest, simplest and most of-
ten used modifications to oligonucleotides. The methyl group decreases the 
susceptibility to nuclease degradation, and improves binding affinity to RNA 
compared to unmodified sequences. Fully-modified OMe oligonucleotides 
have been used to correct aberrant exon splicing in cells50, and mixed back-
bone OMe/DNA hybrid antisense oligonucleotides are also being pursued in 
clinical studies. Hutvàgner et al. successfully demonstrated inhibition of let-
O
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7 function in HeLa cells, as well as C. elegans larvae, using 31-mer OMe-
AMOs51. 
 
2’-O-Methoxyethyl (MOE)-modified oligonucleotides have higher affinity 
and specificity to RNA than their OMe-analogs52. Concerning their applica-
tion in miRNA research, Esau et al. transfected separately MOE-AMOs target-
ing 86 human miRNA into cultured human preadipocytes to address the role 
of miRNAs in adipocyte differentiation. By following gene expression pro-
files of five marker genes, they found miR-143 to be involved in this process 
through regulation of ERK5 protein levels. Treatment of adipocytes with a 
MOE AMO complementary to miR-143 effectively inhibited the differentia-
tion process, whereas negative controls were inactive.  
Locked nucleic acid (LNA)-modified oligonucleotides are distinctive 2’-
O-modified RNA in which the 2’-O-oxygen is bridged to the 4’-O-position via 
a methylene linker to form a rigid bicycle, locked into a C3’-endo (RNA) 
sugar conformation. The LNA modification leads to the thermodynamically 
strongest duplex formation with complementary RNA known and conse-
quently, a biological activity is often attained with very short LNA oligomers. 
Furthermore, LNAs display excellent mismatch discrimination, resistance to 
enzymes and they show a serum decay and a tissue distribution similar to 
that of phosphorothioate oligonucleotides53. 
Mixed LNA/DNA AMOs potently abolished miR-32 function in PFV-1 in-
fected HeLa cells and led to the accumulation of viral mRNA, resulting in in-
creased production of viral progeny54. Recently, Chan et al. have successfully 
applied 2’-O-methyl- and DNA/LNA-mixed oligonucleotides to specifically 
knockdown miR-21 in order to investigate the potential contribution of this 
miRNA in the regulation of apoptosis-associated genes in glioblastoma cell 
lines46.  
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Synthetic ONs with electrically neutral backbones have also shown great 
promise as steric block antisense agents. For example phosphorodiamidate 
morpholino oligonucletides (PMOs) or their conjugates with a cell-
penetrating peptide (CPP) have been applied very effectively for inhibition 
of RNA function by blocking mRNA translation55, redirection of splicing56 
and more recently as microRNA antagomiR57. Due to the neutral backbone, 
morpholino oligomers are less likely to form undesired interactions with 
cellular proteins, especially when used at high concentration. Recent reports 
indicate that morpholino oligonucleotides allow a selective control of gene 
expression; for example, MOs microinjected into a zebrafish, sea urchin or 
xenopus embryos block gene expression and exert effects during the early 
stages of development57. 
Other synthetic oligonucleotides are Peptide Nucleic Acids, to which the 
next section is dedicated, as they have been the focus of these studies58. For 
inhibition of gene expressions they appear to be more effective than other 
antisense molecules, because of their neutral backbone, that allow the mole-
cule to invade local RNA secondary structures more efficiently, making  ac-
cessibility less of an obstacle than it is for other types of oligomer.  
Recently, studies described in literature have proposed an alternative 
strategy for micro-RNAs inhibition. Such method involves targeting of 
miRNA precursors (pre-miRNA) using synthetic oligonucleotides or analogs 
with the following features59: 
1) High binding affinity  and binding specificity  for RNA targets; 
2) Complementary sequences to "sense" strand of pre-miR; 
3) Excellent capacity to stably hybridize their targets; 
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Thus, the maturation of microRNAs and therefore the processing by nucle-
ases are inhibited and the result of this leads to a net reduction of miRNAs in 
the cell60. 
It has been reported that single nucleotide polymorphism (SNPs) or mu-
tation located in miRNAs regions might change the processing of miRNA as 
well as alter the target binding affinity and specificity61. Hoffman et al. re-
ported that the risky miR-196a2-C allele led to more efficient processing of 
the miRNA precursor to its mature form as well as enhanced capacity to 
regulate target genes62. 
Several studies have reported that the sequence variations in pre-miRNA 
may affect the maturation process of miRNAs and binding activity to their 
target mRNAs. Jazdzewski et al. proposed that decreasing pri-miR-146a nu-
clear processing efficiency also mature miRNA production is reduced and 
this resulted in less efficient inhibition of target gene like TRAF6, IRAK1 and 
PTC163.  
Evidence suggests that miRNA expression may be regulated at the level of 
maturation. Some miRNAs in D. melanogaster appear to be processed ineffi-
ciently at early stages of embryonic development64. In the sea urchin 
Strongylocentrotus purpuratus, Let-7 transcripts of about 100 nt are ex-
pressed throughout embryonic development, although mature Let-7   ap-
pears to be only at a later stage23. 
In conclusion the regulation of miRNA expression may occur at multiple 
levels including the two processing steps and the nuclear export step. 
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1.2. PEPTIDE NUCLEIC ACID 
 
Peptide nucleic acids (PNA) originated from efforts during the 1980 in or-
ganic chemist Prof. Ole Buchardt’s laboratory in Copenhagen together with  
biochemist Peter Nielsen to develop new nucleic acid sequence-specific re-
agents.  PNA are  synthetic analogues of DNA and RNA,  in which the natu-
rally occurring sugar-phosphate backbone has been replaced by N-(2 -
 aminoethyl)-glycine units. A methylene carbonyl linker connects natural as 
well as unusual (in some cases) nucleotide bases to this backbone at the 
amino nitrogens65 (Figure 7).  
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Figure 7  Chemical structure of PNA (right) and of DNA (left) 
 
 
This simple and yet entirely new synthetic molecule has an interesting 
and non prototype chemistry. PNAs are non-ionic, achiral molecules and are 
not susceptible to hydrolytic (enzymatic) cleavage. Despite all these varia-
tions from natural nucleic acids, PNA is still capable of sequence- specific 
binding to DNA as well as RNA, obeying the Watson-Crick hydrogen bonding 
rules. Usually PNA is represented as a peptide, with the N-terminus side to 
the left (or upward) and the C-terminus side to the right (or down) and 
unlike DNA and RNA, PNA recognizes and binds complementary strands in 
both parallel and antiparallel orientations (Figure 8). In the antiparallel hy-
bridization PNA’s N-terminus binds to DNA’s 3’end, while its C-terminus hy-
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bridize to DNA’s 5’end. In contrast, in the parallel hybridization PNA’s N-
terminus binds to DNA’s 5’end, while its C-terminus hybridize to DNA’s 
3’end.  
 
 
 
 
 
 
 
 
Figure 8: Parallel and anti parallel orientation of PNA:DNA duplexes 
 
However, the antiparallel orientation illustrated in Figure 9 was found to 
be more stable. Although the PNA’s chemical structure is totally differ-
ent from that of  natural nucleic acids, hybridization properties of PNAs are 
not only preserved, but improved. 
 
 
 
 
 
 
 
 
 
 
Figure 9: Preferred orientation of PNA:DNA duplexes 
 
In fact, the uncharged nature of the PNA backbone is an important feature 
that renders  the binding affinity between  PNA/DNA strand much stronger 
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than that between DNA/DNA strands, just because of the absence of electro-
static repulsion. 
The uncharged nature of PNA is responsible for an enhanced thermal sta-
bility of PNA–DNA duplexes compared with the DNA–DNA equivalents66. 
The neutral amide backbone also enables PNA to hybridize to DNA-
molecules in low-salt conditions because no positive ions are necessary for 
counteracting the interstrand repulsion that hampers duplex formation be-
tween two negatively charged nucleic acids. Consequently, the abundance 
and stability of intramolecular folding structures in the DNA or RNA analytes 
are significantly reduced, making the molecules more accessible to comple-
mentary PNA oligomers. 
Furthermore, PNA is stable across a wide range of temperatures and  pHs, 
unlike DNA, which depurinates at acidic conditions67. However, under  
strong alkaline conditions (pH >11), a rearrangement of the PNA molecules 
might occur68. Additionally, PNA is resistant to nucleases and  proteases. 
 A strong binding affinity together with the higher sequence specificity of 
PNA results in a superior activity of antisense PNAs compared with some 
oligonucleotide derivatives, such as morpholino and 2’-O-methoxyethyl 
modified derivatives.  
Nevertheless, similar to regular oligonucleotides, the equilibrium mis-
match discriminative ability of mixed-base PNAs rapidly declines with in-
creasing length PNA oligomers  because, in this case, sequence specificity 
also anticorrelates with an increase in affinity. It is worth noting that 8–
15mer PNA probes carrying all four nucleobases show good selectivity for 
single-stranded DNA targets during PNA-based affinity electrophoresis and 
on PNA microarrays, whereas longer, 16mer mixed-base PNAs exhibit some 
problems with sequence specificity (15mer probes are required for target-
ing unique sites in entire genomes). 
 
32 
 
1.3. PNA:  APPLICATIONS 
 
 
Because of their high thermal stability and resistance to proteases and 
nucleases enzymes, PNA are ideal candidates for the artificial modulation of 
gene expression and currently they are used not only as potential therapeu-
tic agents, but also as powerful tools in molecular biology and in diagnostics. 
 
1.3.1. THERAPEUTIC APPLICATIONS 
 
Peptide nucleic acids have promise as candidates for gene therapeutic 
drugs design. 
In literature it was reported that the action of PNA on gene expression can 
occur through different mechanism: antigene, antisense and decoy (Figure 
10).  
 
 
Figure 10: Different strategies for gene regulation using PNAs: antisense, blocking trans-
lation from mRNA into protein or regulating splicing of pre-mRNA; anti-gene, blocking 
transcription from DNA to mRNA; decoy, scavenging transcription factors; anti-miR, pre-
venting micro- RNA activity. 
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 Antisense strategy 
 
An antisense oligonucleotide binds specifically a region of mRNA through 
Watson-Crick base pairing, disrupting the translation in the corresponding 
protein. The mechanism used by ON to produce an antisense action has not 
yet been unequivocally defined, and data in literature show that the inter-
ference could be ascribed to two different mechanisms. 
The first mechanism provides that the high binding affinity of ON with 
RNA target blocks the translation process because of steric hindrance.  
Therefore the ON/RNA complex would prevent the RNA interaction with ri-
bosomes required in protein synthesis. 
The second and most accredited antisense  mechanism assumes the acti-
vation of an enzyme, Ribonuclease H, which specifically degrades only the 
mRNA strand of the ON/RNA duplex. 
PNAs are a class of modified oligonucleotides  that are not able to stimulate 
Ribonuclease H when they form a complex with RNA target44. Normally, the 
peptide nucleic acid antisense effect is based on the steric blocking of either 
RNA processing, transport into cytoplasm, or translation. 
It has been concluded from the results of in vitro translation experiments 
involving rabbit reticulocyte lysates that both duplex- (mixed sequence) and 
triplex-forming (pyrimidine-rich) PNAs are capable of inhibiting translation 
at targets overlapping the AUG start codon. Triplex-forming PNAs are able to 
hinder the translation machinery at targets in the coding region of mRNA. 
However, translation elongation arrest requires a (PNA)–RNA triplex and 
thus needs a homopurine target of 10–15 bases. In contrast, duplex-forming 
PNAs are incapable of this. 
Triplex-forming PNAs can inhibit translation at initiation codon targets and 
ribosome elongation at codon region targets. 
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It has been reported that antisense PNAs alter the pre-miRNA splicing of 
the murine interleukin receptor IL-5R, thus resulting  potentially  useful in 
inflamatory deseases’s  treatment such as eosinophilic syndromes69.  
Mologni et al. showed that antisense PNA directed against the gene of the 
retinoic acid receptor (RAR) carried out a 90% inhibition of the target gene’s 
expression70. 
M.J. Gait et al. and others have shown that PNAs, especially when conju-
gated to CPPs, have high efficiency in many RNA targeting applications, for 
example in inhibition of bacterial mRNA translation, inhibition of HIV-1 Tat-
dependent trans-activation and RNA reverse transcription and as splicing 
redirection agents71. 
PNA has also been used  to inhibit gene expression in vivo, thus making 
possible their use as antibiotics72. 
 
 Antigene strategy  
For what concerns the  antigene strategies for laboratory experimenta-
tion, the gold standard is the gene knockout achieved by homologous re-
combination, whereas an alternative option is based on the use of synthetic 
oligodeoxynucleotides capable of hybridizing with double-stranded DNA to 
form a triple-stranded molecule. In this case the gene is not altered but its 
transcription is inhibited either by preventing unwinding of the duplex or by 
preventing the binding of transcription factors to the promoter of the gene. 
Peptide nucleic acids are capable of arresting transcriptional processes by 
virtue of their ability to form a stable triplex structure or a strand-invaded 
or strand displacement complex with DNA (Figure 11)73.  
Such complexes can create a structural hindrance to block the stable func-
tion of RNA polymerase and thus are capable of working as antigene agents. 
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Figure 11: Transcription inhibition through triple-helix formation. 
 
Transcriptional inhibition is accomplished by homopyrimidine PNAs that 
form invasion triplexes either at the promoter or the coding region of the 
gene. Evidence from in vitro studies supports the idea that such complexes 
are indeed capable of affecting the process of transcription involving both 
prokaryotic and eukaryotic RNA polymerases. PNA targeting  the promoter 
region can form a stable PNA–DNA complex that restricts the DNA access of 
the corresponding polymerase. PNA strand displacement complexes, located 
far downstream from the promoter, can also efficiently block polymerase 
progression and transcription elongation and thereby produce truncated 
RNA transcripts; 
Therefore it can be deduced that the PNA antigene application is re-
stricted to the poly-purine parts of genome. 
The PNA2/DNA triplex arrests transcription in vitro and is capable of acting 
as an antigene agent. But one of the major obstacles to applying PNA as an 
antigene agent is that the strand invasion or the formation of strand dis-
placement complex is rather slow at physiological salt concentrations. 
Several modifications of PNA have shown improvement in terms of binding. 
Modifications of PNA by chemically linking the ends of the Watson-Crick and 
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Hoogsteen PNA strands to each other, introducing pH-independent pseudoi-
socytosines into the Hoogsteen strand, incorporating intercalators , or posi-
tively charged lysine residues) in PNA strand can drastically increase the as-
sociation rates with dsDNA. 
Using conjugation with a nuclear localization signal, a PNA directed 
against c-myc gene has been vehicled into the nucleus and an antigenic ef-
fect was observed74. It has also been shown that antigen PNAs directed 
against N-myc DNA can cause dramatic effect on cell proliferation of human 
tumor cells of neuroblastoma. 
 
 Decoy strategy: 
 
Transcription factors recognize exogenous oligonucleotide as target and 
bind to it, resulting in inability to reach the real DNA target.  Few studies 
proved the success of PNA as decoy75. In fact PNA/PNA duplex or PNA/DNA 
duplex are not recognized by transcription factors because of their struc-
tural differences with the natural duplex. 
To overcome the problem, the so-called  DNA-PNA  chimeras (PNA-DNA 
hybrid sequences linked covalently to each other) have demonstrated to be 
useful tools. In this case the PNA acts as a recognition sequence and the DNA 
acts as a substrate for proteins that interact with DNA (nucleases, transcrip-
tion factors). 
 
 
1.4. PNA DELIVERY 
 
One of the most important problems about the use of PNA in therapy is 
related to their low uptake of these molecules in cells. 
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Because of the absence of charged groups in the backbone,  PNAs have 
low solubility and strong tendency to aggregate. It has been observed that 
the solubility decreases with increasing in length of the PNA oligomer and 
the number of purines in the sequence76.  
To improve the solubility and  therefore the delivery it is possible to conju-
gate charged molecules such as amino acids to one of two ends, or use modi-
fied PNA monomers in which the glycine  unit  is replaced by amino acids 
with charged side chains. 
PNA-DNA chimeras were also designed both  to improve  the low cellular 
uptake and the low solubility of PNA and both to  obtain molecules with 
structural and biological properties similar to DNA. 
 
 
 Unmodified PNA delivery 
 
A large variety of cellular transport systems have been developed and 
tested. These systems can be divided into two categories, those based on the 
PNA as they are and those using modified PNA, ie, conjugated to appropriate 
ligands, such as "carriers"  peptides or "guide" sequences77. The first genera-
tion of vectors  is represented by liposomes, colloidal vesicles generally 
composed of a double layer of phospholipids and cholesterol. Liposomes 
may be neutral or cationic, depending on  the phospholipids nature. The nu-
cleic acid can be easily encapsulated inside the liposome, which contains an 
aqueous compartment, or it can be anchored to the surface through electro-
static interactions. These carriers, because of their positive charge, have 
high affinity for cell membranes, which are negatively charged in physiologi-
cal conditions. 
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These systems are internalized through endocytosis.  For example, it is 
possible to internalize them by diffusion, creating transient pores in the 
membrane by electroporation78 or by microinjection79. 
Some studies have also reported the direct transport of PNA in a cell without 
the use of  any  mentioned protocols. However, in this case, the high PNA 
concentrations that is required  (20μM) increased greatly the risk of toxic ef-
fects. 
 
 Modified PNA delivery 
 
The conjugation of PNAs  with  molecules recognized by the cells appears 
as a simple and convenient alternative to the standard translocation tech-
niques mentioned above. 
In this context, mention should be made to the conjugation of PNA with 
guide ligands, which can  interact with specific receptors and can carry  PNA 
only in target cells, in order to reduce undesired side effects in normal cells,  
according to an endocytosis  receptor-mediated mechanism. 
This mechanism requires the existence of transmembrane proteins, de-
fined receptors, that interact specifically with certain molecules in the ex-
tracellular fluid. 
Although the transport receptor mediated is a highly specific process, how-
ever it is not always effective, probably because of the limited amount of 
available receptors on the cell surface and the entrapment  in endosomes / 
lysosomes of the transported material80. 
An alternative strategy involves the use of "Trojan peptides", reported to 
have a general cell membrane-penetrating capacity and  capable of trans-
porting a conjugated cargo to the interior of the cells81. 
These peptides are suggested to work by a receptor independent mecha-
nism, through a physical interaction with components of biologic mem-
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branes, resulting in inverted micelles that allow the passage of water-soluble 
molecules to the interior of the cells. However, the exact mechanism under-
lying the membrane passage of these peptides is still largely unknown 82.  
This class of peptides consists of a series of positively charged peptides, in-
cluding certain domains of the HIV regulatory protein, Tat83, and the Droso-
phila homeodomain transcription factor, Antennapedia84. For their ability to 
cross the cell membrane, these peptides have been called "cell-penetrating 
peptides" (CPP). Peptides are generally composed of about thirty or less 
amino acid residues  and they have a net positive charge. 
The first CPP shown to be capable of carrying PNA oligomers in cells is 
derived from the third helix of the Antennapedia protein's homodomain85. 
Since then, the number of peptides (or derivatives from proteins found in 
nature, both designed and synthesized) with this capacity is gradually in-
creasing.  
Interaction of CPP and cargo is either achieved by covalent attachment or by 
non-covalent complexation through mainly ionic interactions (Figure 12).   
 
 
 
Figure 12: Principles of peptide-based nucleic acid delivery systems. 
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In case of non-covalent complex formation, a further assembly of 
cargo/carrier complexes occurs, leading to the formation of nanoparticles.   
In case of covalently joined molecules a similar scenario is less likely, yet 
cannot be excluded. Prior to the translocation process the particles attach to 
the cell surface by ionic interactions of positively charged CPP residues with 
negatively charged membrane components. Subsequently, complexes are 
taken up by directly penetrating the cell  membrane or by an endocytotic 
pathway. Recent data suggest that the main uptake route is endocytosis.  
Though, direct penetration cannot be excluded and may occur simultane-
ously (depicted by dashed, grey arrows). Once inside the cell, the cargo has 
to reach its target. Depending on the mechanism of uptake several scenarios 
like ‘endosomal escape’ are feasible.  
PNAs conjugated to such peptides have been studied in several cell types 
(Figure 13). Corey’s group found that a PNA conjugated to the Antennapedia 
peptide was internalized in human prostate tumor-derived DU145 cells, giv-
ing rise to vesicular staining of the cells. Vesicular staining of the cytoplasm 
is expected from a mechanism involving (receptor-mediated) endocytosis.  
Other investigators have observed diffuse cytoplasmic and nuclear stain-
ing in Bowes cells after treatment of a PNA conjugated to penetratin (as well 
as transportan), as would be expected from the proposed mechanism of 
these peptides86. 
 
 
Figure 13. Sequences of classical CPPs 
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It is also worth noting that the therapeutic potential of conjugated PNA-
peptide may be limited by the fact that peptide motifs, although covalently 
linked to the PNA, have low stability in biological fluids and are inevitably 
subject to enzymatic degradation. Therefore, studies have shown that it is 
possible to improve the stability of peptides using D amino acids in order to 
make the peptide more resistant to protease degradation and therefore a 
better carrier of PNA. The use of D-amino acids, however, can cause a de-
crease in terms of biological activity.  
This problem can be avoided by employing the so-called retro-inverse 
peptides, which, besides being more resistant to enzymatic degradation, 
maintain their biological activity intact. In fact Aldrian-Herrada et al. have  
claimed that neuronal cells readily take up PNAs conjugated to a retro-
inverso derivative of the pAnt peptide, causing diffuse cytoplasmic as well as 
nuclear staining of the cells87 . 
 
 
 PNA delivery in nucleus 
 
Two factors were identified as prerequisites for effective translocation to 
the nucleus: a) an efficient transport of cargo in the cytoplasm (discussed 
above);b) a nuclear localization sequence accessible and biologically active. 
Regarding the second aspect, very useful for nuclear uptake proved to be the 
so-called topogenic sequences88. They are usually short and strongly basic 
peptide sequences, consisting of sequences of lysine or arginine interrupted 
by other amino acids, often neutral and hydrophobic.  
These sequences are signals that are recognized and bound by receptors 
on the surface of the nuclear pores. 
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These pores play an important role to let pass freely ions and small mole-
cules through the membrane and selectively control the transport of larger 
molecules.  
After recognition and binding, ATP-dependent mechanism drives the mole-
cule through the pore complex, inside the nucleus. The first of these se-
quences has been identified on the viral protein T antigen of SV4089. 
To simultaneously ensure an efficient passage through the plasma mem-
brane and also an effective nuclear uptake, Braun and his team have synthe-
sized a PNA conjugated to a peptide capable of passing the cell membrane 
(pAntp) and another PNA conjugated to an NLS peptide as a carrier system 
within the nucleus90. The efficiency of this complex has been successfully 
tested on human prostate cancer cells: the entry into the cytoplasm is visible 
after an hour and the entry into the nucleus becomes visible  already after 
three hours. 
The following table shows some examples of nuclear localization signal. 
 
 
Table 3: Nuclear Localization Signal 
 
In recent years a valid alternative to the approaches presented above in-
volves chemical modification of the first generation PNA in order to improve 
those negative characteristics previously presented, such as cellular uptake. 
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AIMS OF THESIS WORK 
 
 
The proposed thesis work was carried out pursuing the following objectives: 
 
1) Development of a new strategy for the manual solid phase synthesis 
of Peptide Nucleic Acids. 
 
2)  Synthesis of oligomers consisting of peptide nucleic acid units and 
Peptide Nucleic Acids and Peptide conjugates to target pre-miRNA in-
volved in human diseases such as Hsa-miR-210. 
 
3) Design and synthesis of novel PNA analogues, in particular PNA with a 
sulfate group in  position  of the backbone, in order to evaluate if and 
how modifications in the structure may affect physical, chemical 
properties (i.e. in terms of improved affinity for the target, increased 
solubility in water, etc.) and biological activity of PNA. 
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CHAPTER 2 
 
2.  DEVELOPMENT OF AN EFFICIENT AND LOW COST PROTOCOL FOR THE 
MANUAL PNA SYNTHESIS BY FMOC-CHEMISTRY.  
 
Due to the need of obtaining a large number of PNA oligomers in the 
course of these studies, the first significant aim of this thesis work has been 
the development of an efficient and low cost protocol for the manual PNA 
synthesis by Fmoc-chemistry. Generally, synthesis of PNA oligomers has 
been carried out using a variety of monomers and coupling conditions. Ex-
amples of protecting groups employed for the PNA monomers are repre-
sented by Boc/Z, Fmoc/Z, Fmoc/Boc, Mmt/acyl, Fmoc/acyl, Dde/Mmt,  
NVOC/acyl, azide/Bhoc and Fmoc/Bhoc91. So far, only two kinds of PNA 
monomers are commercially available, protected with the Boc/Z and the 
Fmoc/Bhoc (Figure 14).  
 
 
 
 
 
 
 
 
Figure 14: Commercially available PNA monomers for solid synthesis 
 
Oligomerization conditions are usually set up considering the stability of 
the exocyclic amine protecting groups, the specific base sequences, the na-
ture of the resin, other than the protecting group on the backbone amine. 
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  The Fmoc/Bhoc combination of protecting groups is largely the most 
employed, due to the mild treatments for the cleavage of the oligomer from 
the resin and removal of Bhoc groups. Yields of oligomers depend on several 
factors, including the type of activator, the reaction time, the monomer ex-
cess, the pre-activation time, the times the coupling is repeated, the length of 
the oligomers, the temperature92. Syntheses of sequences with a high con-
tent of purines often give poor yields due to the difficulty of coupling very 
hindered monomers; furthermore expecially when using Fmoc protected 
monomers low yields may originate from aggregation of the peptide nucleic 
acid and stacking of the fluorenylmethoxycarbonyl with the nucleobases. 
Nowdays PNA syntheses are usually carried out on automated synthesizers, 
under controlled and standardized conditions.  
Protocols for the manual synthesis are often an adaptation of protocols 
employed in automated synthesis. The synthesis by Fmoc chemistry of PNA 
oligomers relies on the protocol developed by Egholm and Casale for the 
automated synthesis of PNA oligomers using Fmoc/Bhoc protected PNA 
monomers. In this protocol 5 equivalents of PNA monomer are initially pre-
activated with HATU in the presence of the bases DIPEA and 2,6 lutidine and 
coupled for 20 minutes. Published protocols report manual synthesis with a 
number of PNA monomer equivalents for coupling ranging from 3 to 893.  
When PNA monomers are coupled manually adapting the Egholm proce-
dure, the coupling times are extended at least to 1 hour to increase the reac-
tion yield. The coupling time is extended to 6 hours when 3 equivalents of 
PNA monomers are used, with HOBT/HBTU as activators and DIPEA as a 
base to get quantitative coupling. When polypurine stretches have to be syn-
thesized couplings need to be repeated to obtain the desired oligomer. Over-
all, the combination of large excesses of PNA monomers, the use of HATU as 
activator, the increase in reaction times result in a very expensive and time 
consuming synthesis.  
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2.1. RESULTS AND DISCUSSIONS 
 
 
With the aim of developing an efficient and low cost protocol for the man-
ual synthesis of PNA oligomers by Fmoc chemistry, we have explored a new 
combination of activators and bases (Figure 15).  
 
 
 
 
 
 
 
 
Figure 15: PNA synthesis 
 
 
First of all, PNA oligomers were synthesised for reference by standard 
conditions, using 5 equivalents of PNA monomers activated with HATU (4 
equivalents), in the presence of DIPEA (5 equivalents) and 2,6 lutidine (7.5 
equivalents) for 1 minute and coupled for 20 minutes. The deprotection was 
carried out by treatment of the resin bound PNA with 20% piperidine in 
DMF, and capping steps were always carried out with a single treatment 
with a solution composed of 15/15/70 acetic anhydride/DIPEA/DMF v/v/v. 
Cleavage and deprotection were carried out with TFA/m-cresol 80/20 v/v, 
90 minutes. Four PNA sequences with a length ranging from 9 to 12 bases 
were obtained, following the standard and the new protocols. (see Table 4 
for sequences). 
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Sequence (name) 
 
 
% 
purine 
 % Yields 
 
Standard 
Protocol 
 
Protocol 
1 
 
Protocol 
2 
 
Protocol 
3 
CACACTGTC (PNA 1) 33 19 75 18 45 
ACGCACACTGTC (PNA 2) 42 0 45  <10 56  
AGACGACCCA (PNA 3) 60 63 68 41 56 
GGCCGGGACACA (PNA 4) 70 24 65 50 75 
Table 4: Four PNA sequences choosen. 
 
As sequences containing long stretches of purines are hard to synthesize, 
due to the toughness of coupling sterically hindred monomers such as ade-
nine and guanine to each other, the protocols were tested on PNA oligomers 
having a purine content ranging from 30 to 67%. In all the cases only gua-
nine monomers were double coupled.  
These studies started checking protocols for Fmoc peptide and PNA syn-
thesis, looking for conditions in which very little amounts of aminoacid/PNA 
and different combinations of bases and activators were employed. In this 
regard a rich font of information is represented by protocols for the coupling 
of modified PNAs, as those bearing side chains on the backbone.  A protocol 
described by Le Chevalier Isaad  et al  reports the efficient  synthesis of a 
peptide by manual coupling using only 2.5 equivalents of aminoacids acti-
vated with an equal amount of HOBT/TBTU, in the presence of N-methyl 
morpholine (NMM) as a base94. For the synthesis of PNAs,  the protocol re-
ported by Gogoi (3 equivalents of Fmoc/Bhoc monomers activated with 
HOBT/HBTU in the presence of DIPEA- coupling time 6 hours) was consid-
ered93a. Therefore investigations could reasonable begin changing the acti-
vator HATU for the combination HOBT/HBTU and improve the coupling 
conditions with the use of different bases. The first trials were carried out on 
two PNA sequences: one 9-mer and one 12 mer with a content of purines re-
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spectively of 33% and 42% (Table 4, PNA 1 and PNA 2). The synthesis scale 
was 2 mol; PNAs were elongated on the PAL-PEG PS resin (0.19 mmol/g).  
The efforts were initially devoted to replace HATU using 5 equivalents of 
PNA monomers, activated with HOBT/HBTU. The PNA monomers (5 equiva-
lents) were dissolved in a solution of HOBT/HBTU (5 equivalents) in DMF, 
adding as a base N-methyl morpholine (NMM) (5 equivalents) dissolved in 
DMF. (Pre-activation time: 1 minute) Oligomers were obtained using repeti-
tive cycles of deprotection, coupling and capping. Coupling time was set at 
20 minutes. Yields were judged at the end of the synthesis after analysis of 
the LC-MS profiles of the crudes. The results obtained with these protocols 
were unsatisfactory. The desired oligomers were not obtained, while we 
could see many deletes. NMM is a weak base, with a Kb around 10-7, much 
lower as compared to the Kb for DIPEA. It was reasonable to think to com-
bine it with a larger amount of another very weak base, pyridine (Kb 10-9), 
which is also a good co-solvent for PNA monomers. So the combination of 
NMM with pyridine was investigated. Syntheses were carried out as de-
scribed earlier, but coupling was carried out using a solution of NMM (5 
equivalents) in pyridine.  
The amount of pyridine in the coupling mixture is 25% (Protocol 1); this 
quantity does not cause cleavage of the N-terminal Fmoc. Interestingly the 
desired oligomers were obtained . A comparison of the LC-MS profiles of the 
crudes obtained  with the new protocol (HOBT/HBTU/NMM/pyridine) and 
the standard protocol (HATU/DIPEA, 2,6 lutidine)  revealed that yields using 
the new coupling conditions  were significantly improved, as demonstrated 
by the LC profile in which the desired oligomer now corresponds to the ma-
jor peak (for PNA 1 see Figure 16, compare panels A and B). Encouraged by 
these results we tasted the same protocol on two more sequences, a 10-mer 
and a 12-mer with a content of purines respectively of 60 and 67% (PNA 3 
and 4),. The PNA oligomers were successfully obtained. The LC-MS profiles 
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in fact show a major peak, containing a single product with the mass corre-
sponding to the desired oligomer. The LC profile for PNAs 3 and 4 are shown 
in Figure 16, (compare panel A with B).  Next the synthesis of PNA oligomers 
reducing the amount of PNA equivalents, from 5 to 2.5, was explored. All oli-
gomers were synthesized using 2.5 equivalents of PNA monomers, activated 
with an equal amount of  HOBT/HBTU and 2.5 equivalents of NMM in pyri-
dine as a base (Protocol 2). Syntheses yielded the desired products, although 
in reduced yields, as compared to those obtained using Protocol 1 (Table 4). 
Finally the effect of increasing the amount of bases was investigated. All 
PNAs were synthesised using 2.5 equivalents of PNA monomers, activated 
with an equal amount of HOBT/HBTU and 5 equivalents of NMM in pyridine 
(Protocol 3). The percentage of pyridine in the coupling mixture is now 40. 
The results showed that yields of PNAs doubling the amount of bases with 
2.5 equivalents of PNA monomers (Protocol 3) were in average comparable 
to those obtained with 5 equivalents of PNA and lower content of bases 
(Protocol 1) (Table 4).   
It is likely that doubling the NMM speeds up the formation of the inter-
mediate active ester (as observed in peptide synthesis) and this effect coun-
terbalances the decrease of the equivalents of PNA monomers.17 The com-
parison of the LC profiles obtained with Protocol 3 is shown for three se-
quences, respectively in Figure 16, letter C. 
Furthermore in all cases yields obtained using Protocol 3 were comparable 
or higher than to those obtained with the standard protocol, even for se-
quences with the higher content of purines (Figure 16, letter C and Table 4).  
These results suggest that HATU is not necessary for the PNA coupling; 
the mixture HOBT/HBTU gives very good yields of coupling especially when 
combined with pyridine/NMM. 
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Figure 16: LC profile for the crudes obtained for  PNA1, PNA3 and PNA4 with standard 
protocol (A), protocol 1 (B) and protocol 3 (C). The peak labelled with the asterisk corre-
sponds to the desired product. 
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2.2. CONCLUSIONS 
 
In conclusion it was demonstrated that the manual coupling of 
Fmoc/Bhoc PNA monomers  is very efficient using HOBT/HBTU as activa-
tors in the presence of NMM/pyridine as bases.  The protocol developed is 
robust and low cost and can be executed by an automated PNA synthesizer.  
Interestingly the addition of large amounts of pyridine contributes to in-
crease the yields of oligomers with high content of purines, as demonstrated 
for PNA 4 (content of purine 67%), in which very high yields are obtained 
even when the equivalents of monomer per coupling are halved.  
Furthermore, the protocol developed will allow the obtainment with good 
yields of difficult sequences, avoiding expensive activators.  
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2.3. MATERIALS AND METHODS 
 
Activators HBTU, HOBT and HATU were purchased at Inbios (Italy). 
Fmoc-PNA-cytosine(Bhoc)-OH, Fmoc-PNA-thymine-OH, Fmoc-PNA-
guanine(Bhoc)-OH, Fmoc-PNA-adenine(Bhoc)-OH were obtained by Link 
Technologies. Acetonitrile (ACN) for LC-MS, N,N-dimethylformamide (DMF) 
for solid phase synthesis, DIPEA, Dichloromethane were from Romil Pure 
Chemistry, N-methylmorpholine from Fluka and piperidine from Biosolve. 
Fmoc-PAL-PEG-PS (0.19 mmol/g) resin was from Applied Biosystems.  
All other chemicals were supplied by Sigma-Aldrich and were used with-
out other purification. LC-MS analyses were performed on a LC-MS Thermo 
Finnigan with an electrospray source (MSQ) on a Phenomenex Jupiter 
5C18 ( 300Å, 150x460 mm) column with a flow rate of 0.8 mLmin-1 at 
65°C. 
 
 
Experimental 
Each PNA oligomer was synthesized on a 2mol scale using both the 
standard PNA protocol and PNA new protocols. The syntheses were per-
formed on a Fmoc-PAL-PEG-PS resin (0.19mmol/g). To improve the cou-
pling efficiency double couplings were carried out on PNA-guanine mono-
mers.  
 
Standard protocol 
Synthesis was carried out using repetitive cycles of deprotection, coupling 
and capping at room temperature. After each of these cycles two flow 
washes (25s) with DMF performed. 
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Deprotection: 20% piperidine in DMF, 7 minutes.  
Coupling: 5 equivalents of  PNA monomers were dissolved in DMF to a con-
centration of 0.22M; A solution of  HATU in DMF 0.18M (4eq) and 50L of a 
mixture of DIPEA 0.2M and 2,6-Lutidine 0.3M in DMF were added. (Pre-
activation time: 1 minute- coupling time:20 minutes) 
Capping: acetic anhydride/2,6 Lutidine/DMF (5/6/89 v/v/v/), 5 minutes. 
At  the end of the synthesis the resin was washed with DMF, DCM, diethyl 
ether and dried in vacuo. The PNA oligomers were cleaved from the resin 
and deprotected by a treatment with a solution of TFA/m-cresol (80/20) 90 
minutes r.t. 
The filtrate was flushed by a stream of nitrogen to remove the most of 
TFA and the PNA oligomers were precipitated by addition of cold diethyl 
ether, washed three times with diethyl ether and dried in vacuo. 
 
 
Protocol 1 (5 eq PNA) 
Synthesis was carried out using repetitive cycles of deprotection, coupling 
and capping at room temperature. After each of these cycles two flow 
washes (25s) with DMF were performed. Deprotection, and final cleavage 
were carried out as described in the Standard Protocol. 
Coupling: 5 equivalents of  PNA monomer were dissolved in DMF to a con-
centration of 0.22M;  a solution of  HOBT in DMF 0.20M (5 equivalents) and 
a solution of  HBTU in DMF 0.20M (5 equivalents), were added. 50L of a 
mixture of NMM 0.2M in pyridine were added.  (Pre-activation time: 1 min-
ute- coupling time:20 minutes). 
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Capping: acetic anhydride/2,6 lutidine/DMF (5/6/89 v/v/v/), 5 minutes 
 
Protocol 2 (2.5 eq PNA) 
Synthesis was carried out using repetitive cycles of deprotection, coupling 
and capping at room temperature. After each of these cycles two flow 
washes (25s) with DMF performed. Deprotection, and final cleavage were 
carried out as described in the Standard Protocol. 
Coupling: 2.5 equivalents of  PNA monomer were dissolved in DMF to a con-
centration of 0.22M;  a solution of  HOBT in DMF 0.20M (2.5 equivalents) 
and a solution of  HBTU in DMF 0.20M (2.5 equivalents) were added. 25L of 
a mixture of NMM 0.2M in pyridine were added. (Pre-activation time: 1 min-
ute- coupling time:20 minutes) 
Capping: acetic anhydride/2,6 lutidine/DMF (5/6/89 v/v/v/), 5 minutes 
 
 
 
Protocol 3 (2.5 eq PNA + pyr) 
Synthesis was carried out using repetitive cycles of deprotection, coupling 
and capping at room temperature. After each of these cycles two flow 
washes (25s) with DMF performed. Deprotection and final cleavage were 
carried out as described in the standard Protocol. 
Coupling: 2.5 equivalents of  PNA monomer were dissolved in DMF to a con-
centration of 0.22M;  a solution of  HOBT in DMF 0.20M (2.5 equivalents) 
and a solution of  HBTU in DMF 0.20M (2.5 equivalents), was added. 50L of 
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a mixture of NMM 0.2M in pyridine was added.  (Pre-activation time: 1 min-
ute- coupling time:20 minutes) 
Capping: acetic anhydride/2,6 lutidine/DMF (5/6/89 v/v/v/), 5 minutes. 
The following molecules were obtained (underlined bases were double cou-
pled): 
 
PNA 1      CACACTGTC   
PNA 2       AGACGACCCA   
PNA 3       ACGCACACTGTC   
PNA 4      GGCCGGGACACA  
All products were identified by electrospray mass analysis 
PNA 1 (Da):  Calculated: 2396.2; [M+2H]2+: 1199.1; [M+3H]3+: 799.6;   
[M+4H]4+: 600.0. 
                          Found: [M+2H]2+: 1199.1; [M+3H]3+: 799.8; [M+4H]4+: 599.9. 
 
PNA 2 (Da): Calculated: M=2705.6; [M+2H]2+: 1353.8; [M+3H]3+: 902.9;  
[M+4H]4+: 677.0. 
                           Found: [M+2H]2+: 1352.7; [M+3H]3+: 902.1; [M+4H]4+: 676.8. 
 
PNA 3 (Da): Calculated: M=3124.4; [M+2H]2+: 1608.2; [M+3H]3+: 1072.3; 
[M+4H]4+: 804.5. 
                        Found: [M+2H]2+: 1606.8;  [M+3H]3+: 1071.4; [M+4H]4+: 803.9. 
 
PNA 4 (Da): Calculated: M=3304.4; [M+2H]2+: 1653.2; [M+3H]3+: 1102.5; 
[M+4H]4+: 827.1. 
                        Found: [M+2H]2+: 1652.2; [M+3H]3+: 1101.8; [M+4H]4+: 826.6. 
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CHAPTER 3 
 
 
3. SYNTHESIS AND CHARACTERIZATION OF PNAS FOR TARGETING PRE-
MIRNAS INVOLVED IN HUMAN DISEASES 
 
 
Another significant aim of this thesis work is the synthesis and charac-
terization of PNAs which we will define since now on as antago-premiR, 
designed to inhibit the function of a target miR. This approach is actually 
completely new, and differs from the the antagomiR approach by the fact 
that PNAs will target the precursor of the mature miRNA, the pre-miRNA.  
This strategy is aimed to inhibit maturation of the pre-miRNA into miRNA. 
For the experimental point of view one the advantages recognized by us in 
the present strategy is represented by the unique interpretation of the ex-
perimental  results. When miRNA inhibition is achieved by antagomiRs, 
molecules complementary to the mature miRNA, and the amount of miRNA 
is quantified by RT-PCR, results are often doubtful: the PNA antagomiR, in 
fact, may bind to the primers and thus inhibit their amplification, resulting 
in low yield of amplificates,  which is independent by the desired antagomiR 
function of the PNAs. Anti premiRNA are not fully complementary to the 
miRNA and are not expected to display interference. Furthermore, as pre-
miRNAs are located both in the nucleus and in the cytoplasm there is in 
principle a dual possibility to reach them.  
We designed PNA oligomers and PNA-peptide conjugates fully comple-
mentary to a specific region of the microRNA-210 precursor (pre-miR210). 
In fact, such molecules, pre-antagomir, should bind to the miRNA precursor 
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with high specificity and affinity, blocking the maturation process and so 
preventing the interaction of miR-210 with mRNA. 
 
3.1. MIRNA210 
 
In this work, the studies were focused on microRNA 210, a unique miRNA 
that is evolutionarily conserved and ubiquitously expressed in hypoxic cell 
and tissue types95. It directly represses multiple transcripts associated with 
diverse cellular functions and it has been mechanistically linked to the con-
trol of a wide range of cellular responses known to influence normal devel-
opmental physiology as well as a number of hypoxia-dependent disease 
states, including tissue ischemia, inflammation and tumorigenesis (Figure 
17) 96. Independent pieces of data now exist that link the dynamic regulation 
of miR-210 directly to low oxygen levels as opposed to other mechanisms 
that secondarily associated to hypoxia (i.e., oxidative stress, inflammation 
and others).  
 
Figure 17: miR-210 controls diverse fundamental cellular preocesses 
 
Multiple groups have found that miR-210 is specifically induced by HIF-
1 and is unique in its wide distribution and robust upregulation in re-
58 
 
sponse to hypoxia97. Furthermore, observational evidence suggests that lev-
els of miR-210 are specifically regulated in a number of human disease 
states, indicating an important role for this miRNA in modulating hypoxia-
induced pathogenesis98. miR-210 is also upregulated in a significant per-
centage of human samples derived from primary solid tumors, including 
head and neck cancer, melanoma, glioma, small cell and lung cancer, lung 
adenocarcinoma and adrenocortical carcinoma99. Genomic deletions of miR-
210 have also been reported in human epithelial ovarian cancer samples, 
and these deletions are suggested as a possible trigger to tumorigenesis.  
Correspondingly, Huang and colleagues have demonstrated that forced 
expression of miR-210 in implanted tumor tissue can repress tumor growth 
in immunodeficient mice98. However, upregulated levels of miR-210 in hu-
man breast cancer samples display an inverse correlation with disease-free 
and overall patient survival97a and, in a separate study, miR-210 levels cor-
relate with breast cancer aggressiveness and metastatic potential100. While 
somewhat paradoxical, these findings taken together may indicate that miR-
210 can play either adaptive or maladaptive roles in repressing or disease 
conditions, respectively, depending upon the specific in vivo context.   
Finally, In addition to specialized endothelial functions, developing 
erythroid cells may also depend upon miR-210 to direct specific globin ex-
pression. Through miRNA profiling assays, Bianchi and colleagues have re-
ported that miR-210 is overexpressed in thalassemic patients  and is prefer-
entially upregulated in human erythroid precursor cells displaying a heredi-
tary persistence of fetal hemoglobin (HPFH)101. This upregulation is repli-
cated by treatment of erythroid precursors in cell culture with mithramycin, 
which correlates with induction of fetalglobin expression. Hypoxia has 
previously been reported to alter progression of the erythroid program102 
and is certainly a driving stimulus in erythropoeisis103. Low O2 might indeed 
modulate the relative amounts and types of hemoglobins produced by 
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erythroid cells, leading to increased HbF during stress erythropoiesis. How-
ever, it is unclear if this upregulation of miR-210 in HPFH erythroid cells is 
dependent upon HIF-1α or if miR210 and its direct targets are causatively 
responsible for this regulation.   
Just because miR210 was found to be involved in all biological processes 
described above, in recent years the search for molecules capable of inhibit-
ing its functions through an antisense approach was found desirable.  
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3.2. RESULTS AND DISCUSSION 
 
3.2.1. SYNTHESIS OF THE PNA, PEPTIDE-PNA CONJUGATES 
 
Two PNA sequences targeting  the "sense region" (PNA 5) and the " 5’ end 
region" (PNA 6) of the pre-miR210 were designed. (Figure 18).  
 
 
Figure 18: Pre-miRNA210 targeting by PNA 5 and PNA 6 
 
 
These sequences differ by the corresponding tract of the mature miRNA 
by one or two bases: in the pre-miRNA, in fact, there is not fully complemen-
tarity between bases and PNAs were designed to be fully complementary to 
the pre-miRNA.   
The high affinity and specificity of binding of PNA toward complementary 
RNA should in principle allow the interaction of the PNA with the desired 
RNA target, opening the RNA duplex and thus  inhibiting the miRNA matura-
tion (Figure 19). 
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Figure 19: pre-microRNAs inhibition with PNAs antagomir 
 
 
The chosen sequences are: 
 
PNA 5:                                      NH2-gtgtgcggtg-H 
PNA 6:                                      NH2-aggcactgccgggt-H  
 
In order to improve the cellular uptake of the PNA oligomers and make 
sure the PNAs reach their target miR210, we obtained PNAs conjugated to 
carrier peptides. Since the pre-microRNA 210 is present both in the nucleus 
and in the cytoplasm, we choose different peptides for the delivery in both 
cellular compartments, TAT, NLS, combination of TAT and NLS and biNLS.  
TAT  is a small basic peptide derived from the HIV-1 Tat protein, that has 
been successfully shown to deliver a large variety of cargoes, from small par-
ticles to proteins, peptides and nucleic acids104. The transduction domain  or 
region conveying the cell penetrating properties appears to be confined to a 
small (9 amino acids) stretch of basic amino acids, with the sequence 
RKKRRQRRR; the guanidinium groups of the arginine side chain seems to be 
responsible for the high transfection efficiency83. The TAT peptide has been 
reported to successfully deliver PNA in the cytoplasm in different cell types. 
Bendifallah et al. investigated the relative potency of  different CPPs (Trans-
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portan, oligo-arginine (R7-9), pTat, Penetratin, KFF, SynB3, and NLS), as car-
riers of medicinally relevant cargo and employing a positive assay, showed 
that TAT peptide had a significantly transport capacity105.  Diaz-Mochòn et 
al. synthesized PNA-peptides conjugates and tasted their intracellular deliv-
ery showing that conjugates bearing hepta-arginine peptide and TAT48-57 de-
capeptide were taken up by cells with high efficiency106.  
NLS , a Nuclear Localization Signal, is a short stretch of amino acids that 
mediates the transport of the nuclear proteins into the nucleus107 (Figure  
20). 
 
 
Figure 20: The classical nuclear import cycle. 
 
In the cytoplasm, cargo containing a cNLS is bound by the heterodimeric im-
port receptor, importin/importin .  Importin  recognizes the cNLS, and 
importin  mediates interactions with the nuclear pore during translocation. 
Delivery of PNA conjugated to NLS into the nucleus has been demonstrated 
by several groups108. Tonelli et al., for example, developed an antigène pep-
tide nucleic acid (PNA) for selective inhibition of MYCN transcription in 
neuroblastoma cells,  linked at its amino terminus to a nuclear localization 
signal peptide and they showed through Fluorescence microscopy specific 
nuclear delivery of the PNA in six human neuroblastoma cell lines. 
63 
 
We also obtained a combination of TAT and NLS, in which NLS was an-
chored as a branch on the TAT peptide, after introducing a lysine residue at 
the C terminus position. We wish to verify whether the presence of a double 
cargo affects the delivery and the biological activity of the PNA. 
Finally a new carrier, biNLS was also obtained and conjugated to our PNA.  
These peptide has been reported to bind to both arms of importin   and its 
uptake has been demonstrated to be very high in mammalian cells, yeast and 
plants. Kosugi et al. showed also that the length of the linker region between 
the two consensus sequences of the bi-NLS is a key factor. In fact, an effec-
tive length of the linker would be 10-12 residues, which would be equal to 
the distance between the major and the minor binding sites of importin 109. 
A long linker up to 20 residues makes a bi-NLS as two separate and classical 
monopartite NLSs. 
Follow the sequences: 
 
PNA 5-TAT                      NH2-gtgtgcggtg-GRKKRRQRRRPPQK-H 
PNA 5-NLS                        NH2-gtgtgcggtg-PKKKRKV-H 
PNA 5-TAT-NLS                NH2-gtgtgcggtg-GRKKRRQRRRPPQK- PKKKRKV-H 
NLS-PNA 5-TAT              NH2PKKKRKV-gtgtgcggtg-GRKKRRQRRRPPQK-H 
PNA 6-Bi-NLS                             NH2-aggcactgccgggt-RKRSADFERLYLVPSKK –H 
 
 
 A solid-phase synthesis strategy has been used to obtain the molecules. 
This strategy was originally introduced in 1963 by Merrifield for the synthe-
sis of peptides and today is widely used for the synthesis of many organic 
polymers, such as oligonucleotides, peptides, peptide nucleic acids and oli-
gosaccharides (Figure 21). 
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Figure 21: Solid Phase Synthesis Scheme 
 
Each cycle of synthesis includes a number of consecutive steps: 
 
 Removal of protecting group on the amino terminus; 
 Accurate washing of the resin; 
 Activation of the carboxyl of the residue that has to be coupled; 
 Condensation reaction; 
 Careful wash of the resin; 
 Cleavage from the resin. 
This  strategy can be easily used for the synthesis of PNA oligomers and 
PNA-peptide conjugates.  
PNA 5 was synthesized using a protocol for Fmoc solid-phase synthesis of 
PNA on a 2 mol scale, previously described in chapter 2. To improve the 
synthesis yields double couplings were performed on purine monomers.  
After purification by reverse phase HPLC on semi-preparative scale the 
product was analyzed by electrospray mass spectrometry and UV-visible 
spectroscopy. As expected  the PNA is characterized  by a maximum at 260 
nm, due to the heterocyclic bases, and a maximum at 210 nm, due to peptide 
bonds (Figure 22). 
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Figure 22: LC/MS spectrum of PNA 5 
 
Instead, the PNA 6 oligomer was obtained with very low yields and for 
this reason, we decided to grow this PNA on a peptide to obtain directly the 
PNA-peptide conjugates.  
The synthesis of PNA-peptide conjugates involved the solid-phase synthesis 
of the different peptides, then the growth of the  PNAs chains on the support  
functionalized with the peptide (Figure 23). 
 
 
 
 
 
 
 
 
 
 
 
Figure 23: Conjugation strategy between petides and PNA. 
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The TAT peptide (GRKKRRQRRRPPQK) was anchored to a resin loaded 
with a Lys (Mtt); this residue is functional for the synthesis of the branched 
NLS-TAT.  PNA5 is grown on the peptide loaded resin and the product, the 
PNA-peptide conjugate, is deprotected and cleaved off the resin after treat-
ment with TFA / m-cresol / TIS (78/20/2) v / v / v.  The PNA-peptide con-
jugate was analyzed  by analytical reverse phase HPLC and purified by semi-
preparative  HPLC . The mass analysis of the crude revealed the presence of 
the desired PNA5- TAT conjugate (Figure 24). 
 
 
Figure 24: LC/MS spectrum of PNA 5-TAT crude 
 
PNA5-NLS, NLS-PNA5-TAT, PNA6-Bi-NLS conjugates were obtained fol-
lowing the same strategy described for TAT-PNA 5. Below  LC-MS profiles of 
the expected PNA5-NLS pure is reported as an example (Figure 25). 
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Figure 25: LC/MS spectrum of PNA 5-NLS  
 
To obtain the branched TAT(NLS) PNA conjugate we first obtained the 
TAT-PNA, acetylated at the N-terminus. We next removed the Mtt from the 
side chain of the N-terminal lysine and on this we finally grow the NLS pep-
tide. (Figure 26). 
 
 
 
 
 
 
 
 
 
 
Figure 26: branched NLS-TAT synthesis  
 
The MALDI-TOF mass spectrum of the sample obtained, however, has shown 
a construct whose molecular weight was found to be about 115 units less 
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than the expected weight. The product obtained is probably lacking  the last 
proline of the peptide NLS (spectra not shown).  
 
3.2.2. FLUORESCENCE STUDIES 
 
In order to demonstrate that the PNA was able to bind to the pre-miRNA 
we obtained a Thiazole Orange (TO) modified PNA for fluorescence studies.  
Thiazole Orange (TO) is an asymmetric cyanine dye and a fluorescent DNA 
intercalator110. The functionalization of Peptide Nucleic Acid  oligomers with  
Thiazole Orange has been extensively investigated and it has been shown to 
be one of the most effective fluorescence-based strategies for DNA detection 
involving modified PNA. This positively charged heterocycle, which provides 
a strong fluorescence enhancement upon DNA hybridization, combined with 
a well-known base stacking ability, has been successfully exploited for sev-
eral PNA-based approaches. In previous works, Kubista’s group constructed 
the so-called ‘‘Light-Up’’ probes, made by a TO molecule covalently linked to 
the N-terminus of the PNA oligomers by a linker111. These molecules showed 
a weak fluorescence signal as free probes and a high fluorescence enhance-
ment upon DNA hybridization, revealing their suitability for specific detec-
tion of nucleic acids in homogeneous assays. This strategy was applied to de-
tect post-PCR products with a single mismatch resolution and real time PCR 
detection assays112. TO-modified PNA oligomers have also been successfully 
applied in clinical diagnostic applications113.  
Tonelli et al. showed that TO–PNA probes had a good fluorescence en-
hancement upon hybridization with the target RNA sequence allowing the 
real time monitoring of the transcription-based amplification114. Moreover, 
even in the presence of remarkable amount of non-target RNA, the probe 
fluorescence emission remains low, compared to the free probes. So, the 
PNA probes conjugated with dyes like TO are appropriate tools for real time 
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isothermal assays that target RNA ‘amplicons’115. TO is a florescence interca-
lator successfully employed for DNA detection, linked to synthetic conjugate 
through a linker attached to the quinoline nitrogen of the heterocycle110 
(Figure 27). 
 
 
 
 
 
 
 
 
Figure 27: Thiazole Orange 
 
 The use of TO as fluorophore is compatible with the solid phase synthesis 
protocols commonly applied in the synthesis of PNA, since this molecule is 
stable under the strong acidic conditions used in the final step for cleaving 
the oligomer from the solid support. 
A carboxy-functionalized TO derivative was prepared116, employing 
Lepidine and 6-bromohexanoic acid (Figure 28). 
 
 
 
 
 
 
 
 
 
Figure 28: TO derivative synthetic strategy 
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 The TO derivative was characterized by 1H and 13C NMR and employed for 
the derivatization of the PNA oligomers. 
We derivatized the TAT-PNA 5 with TO. The peptide-PNA conjugate was 
prepared by solid synthesis, employing the same protocol discussed above 
for PNA-peptide conjugates synthesis. The probe was attached to the conju-
gate anchored on the solid support after reaction of 5 equivalents of TO dye 
activated by a mixture of HOBt/HBTU (4.9 eq.) in DMF and  NMM (7 eq.). 
Double couplings of 60 minutes each were performed and the reaction was 
carried in the dark. After cleavage from the resin, the conjugate was ana-
lyzed by analytical reverse phase HPLC and purified by semi-preparative  
HPLC . The mass analysis of the crude revealed the presence of the desired 
TO-PNA5-TAT conjugate (Figure 29). 
 
 
Figure 29: LC/MS spectrum of TO-PNA 5-TAT 
 
 For Fluorescence measurements DNA instead of RNA was employed, due 
to its higher stability. The sequence was a 42 mer DNA (DNA5) encompass-
ing the tract complementary to PNA 5  and having additional bases at the 5’. 
It has been reported, in fact, that TO dye lights up only when binds to com-
plementary sequences at least 28 bases long111.  
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Follow the DNA sequences: 
 
DNA5           CAGGGCAGCCCCTGCCCACCGCACACTGCGCTGCACGTACGT 
DNA5c         CCAGACCCACTGTGCGTGTGACAGCGGCTGATCTG 
 
 According to data reported in the literature, the fluorescence emission of 
free and hybridized probes is different. The TO-PNA was incubated with the 
DNA duplex (DNA5/DNA5c) and the variation in the fluorescence emission 
at 470nm was monitored. An increase in the fluorescence signal was ob-
served, consistent with the hybridization of PNA to the DNA duplex, rea-
sonably occurring after strand invasion (Figure 30). 
 
 
Figure 30: Fluorescence emission of free and hybridized probes. 
 
 Measurements of fluorescence were carried out also on the TO-PNA 5-
TAT /DNA duplex to detect the fluorescence intensity displayed when all the 
PNA hybridize the DNA. Surprisingly the two spectra were found superim-
posable, demonstrating the efficiency in the binding of PNA5 to DNA duplex. 
Reasonably PNA 5 is able to invade the RNA duplex and disrupt it. 
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 Next we had to test the effect of the molecules in cells, to verify either 
their uptake and their activity.  With the aim to verify whether these mole-
cules were capable of entering the cells some of these sequences  were also 
derivatized with a fluorescent probe, FITC (Figure 31), in order to perform  
Fluorescence-activated cell sorting (FACS) experiments too. 
 
 
 
 
 
 
 
 
 
 
Figure 31: Fluorescein isothiocyanate 
 
However, derivatization using the  fluorescent probe requires, first of all, 
the introduction of an adequate linker, to avoid low yields of reaction, due to 
steric hindrance  of the peptide-PNA conjugate. Amino hexanoic acid (HAx) 
was used as a spacer, and in particular the derivative Fmoc-HAx-OH was an-
chored to the PNA-peptides constructs already present on the resin, using 
the protocol described for the peptide solid phase synthesis. Derivatization 
of oligomers by FITC was carried out  incubating the resin bound oligomer 
with a solution of FITC (5 eq.), NMM (7eq.) in DMF.  (Figure 32). All products 
were cleaved off the resin as described earlier for PNA-peptide conjugates. 
Follow the products obtained:  
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FITC-PNA 5-TAT            FITC-gtgtgcggtg-GRKKRRQRRRPPQK-H 
FITC-NLS-PNA5-TAT      FITC- PKKKRKV-gtgtgcggtg-GRKKRRQRRRPPQK-H 
FITC-PNA 6-Bi-NLS              FITC-aggcactgccgggt-RKRSADFERLYLVPSKK –H 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32: Synthesis Strategy for PNAs-Peptides derivatization with FITC 
 
 
Conjugates FITC-PNA5-TAT, FITC-NLS-PNA5-TAT, FITC-PNA6-Bi-NLS  
were obtained after purification  by reverse phase HPLC on semi-
preparative scale and  analyzed by electrospray mass spectrometry and UV-
visible spectroscopy. As expected  the molecules were characterized  by a 
maximum at 495 nm, due precisely to the presence of fluorescein isothio-
urea (Figure 33, Figure 34, Figure 35). 
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Figure 33: LC/MS spectrum of FITC-PNA 5-TAT 
 
Figure 34: LC/MS spectrum of FITC-PNA 6-Bi-NLS 
 
Figure 35: LC/MS spectrum of FITC-NLS-PNA 5-TAT 
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Some of these molecules were employed for FACS (Fluorescence Acti-
vated Cell Sorting) experiments, carried out in collaboration  with the re-
search team of Professor Roberto Gambari of University of Ferrara. 
 Preliminary investigations carried out on the three PNAs functionalized 
with FITC revealed that cells do incorporate FITC modified NLS (or TAT) 
PNAs, although in a lesser extent as compared to polyarginine conjugated 
PNA, as shown clearly in Figure 36. 
 
 
Figure 36: Fluorescence emission of: 1) FITC-PNA5-TAT (green curve); 2)FITC-NLS-
PNA5-TAT (pink curve); 3)FITC-PNA6-BiNLS (light blue curve); Negative control and posi-
tive control are indicated respectively with a black curve and an orange curve. 
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3.3. CONCLUSIONS 
 
 
One aim of this PhD project involved the synthesis of PNA oligomers to 
target microRNA 210 precursor and inhibit miRNA 210 functions, as it is in-
volved in many diseases and many biological processes. We hypothesized 
that PNA hybridizing themiRNA precursor, could act as inhibitor already at 
the level of miRNA maturation process. 
In particular two sequences were synthesized, respectively, complemen-
tary to the “sense region” (PNA5) and the 5' end region (PNA6) of the target 
precursor. Furthermore, in order to enhance the cellular uptake, PNAs were 
conjugated also to a carrier peptide (TAT) and  to two nuclear localization 
signal peptides (NLS, Bi-NLS).  
The ability of PNA oligomers to bind pre-miRNA was assessed by fluores-
cence. A DNA duplex, mimicking the pre-miRNA, was employed to demon-
strate the ability of the PNA to give strand invasion opening the DNA duplex 
and forming a PNA/DNA duplex. After confirming the PNA ability of  hybrid-
izing the target sequence, the next step was to verify in a preliminary man-
ner the cellular uptake  with FACS experiments. The data show qualitatively 
that our conjugates are poorly taken up by cells and likely explains their low 
activity as miRNA nhibitors. 
Future plans will focus precisely on the modification of PNA molecules to 
improve cellular uptake as well as on the synthesis of further sequences 
complementary to other regions of the miRNA precursor. 
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3.4. MATERIALS AND METHODS 
 
Protected N-Fmoc-amino acid derivatives, acetic anhydride, coupling re-
agents and have been purchased from Novabiochem.  Activators HBTU, 
HOBT and HATU were purchased at Inbios (Italy). Fmoc-PNA-
cytosine(Bhoc)-OH, Fmoc-PNA-thymine-OH, Fmoc-PNA-guanine(Bhoc)-OH,  
Fmoc-PNA-adenine(Bhoc)-OH were obtained by Link Technologies.  
Acetonitrile (ACN) for LC-MS, N,N-dimethylformamide (DMF) for solid phase 
synthesis, DIPEA, Dichloromethane were from Romil Pure Chemistry, N-
methylmorpholine from Fluka and piperidine from Biosolve.  
Fmoc-PAL-PEG-PS (0.18 mmol/g) resin was from Applied Biosystems. All 
other chemicals were supplied by Sigma-Aldrich and were used without 
other purification. Preparative purification was carried out on a Shimadzu 
LC-8A, equipped with a SPD-M10 AV diode array detector. Preparative HPLC 
was performed on a Phenomex Jupiter 10μm Proteo (90Ǻ 250 x 10.00 mm) 
column with a flow rate of 5 mLmin-1.  1H NMR spectra were recorded on a  
Varian 400 MHz spectrometer. Proton chemical shifts are reported in 
ppm () relative to the solvent reference relative to tetramethylsilane (TMS) 
(d6-DMSO, d 2.50). Data are reported as follows: chemical shift (multiplicity 
[singlet (s), doublet (d), triplet (t), quartet (q) and multiplet (m)], coupling 
constants [Hz], integration). Carbon NMR spectra were recorded on a Varian 
500 (125 MHz) spectrometer with complete proton decoupling. Carbon 
chemical shifts were reported in ppm () relative to TMS with the respective 
solvent resonance as the internal standard (DMSO, 39.5). 
LC-MS analyses were performed on a LC-MS Thermo Finnigan with an 
electrospray source (MSQ) on a Phenomenex Jupiter 5C18 ( 300Å, 
150x460 mm) column with a flow rate of 0.8 mLmin-1 at room temperature. 
Fluorescence spectroscopy was performed on a Varian Spectrophotometer. 
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3.4.1. PNA 5 synthesis 
 
Synthesis was carried out using repetitive cycles of deprotection, coupling 
and capping at room temperature. To improve the coupling efficiency double 
couplings were carried out on PNA-guanine monomers. After each of these 
cycles two flow washes (25s) with DMF performed. 
 Deprotection: 20% piperidine in DMF, 7 minutes  
 Coupling: 2.5 equivalents of  PNA monomer were dissolved in DMF to 
a concentration of 0.22M;  a solution of  HOBT in DMF 0.20M (2.5 
equivalents) and a solution of  HBTU in DMF 0.20M (2.5 equivalents) 
were added. 25L of a mixture of NMM 0.2M in pyridine were added. 
(Pre-activation time: 1 minute- coupling time:20 minutes). 
 Capping: acetic anhydride/2,6 Lutidine/DMF (5/6/89 v/v/v/), 5 min-
utes. 
At  the end of the synthesis the resin was washed with DMF, DCM, diethyl 
ether and dried in vacuo. The PNA oligomer was cleaved from the resin and 
deprotected by a treatment with a solution of TFA/m-cresol (80/20) 90 
minutes r.t. The filtrate was flushed by a stream of nitrogen to remove the 
most of TFA and the PNA oligomer was precipitated by addition of cold di-
ethyl ether, washed three times with diethyl ether and dried in vacuo and ly-
ophilized . 
PNA 5 purification was carried out by semi-preparative RP-HPLC applying 
a linear gradient of acetonitrile (0.1% TFA) from 5% to50% in 30 min. 5 
mL/min. PNA 5 purity and identity were confirmed by LC-MS system previ-
ously described; A gradient of solvent B (0.05% TFA in CH3CN) from solvent 
A (0.05% TFA in H2O) of 5% to 50% was applied over 30 min. and it was 
identified by electrospray mass analysis. 
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  PNA 5 (Da):  Calculated: 2814.6;  [M+2H]2+: 1408.3; [M+3H]3+: 939.2; 
[M+4H]4+: 704.6. 
 Found: 2815.0; [M+2H]2+: 1408.5; [M+3H]3+: 939.3; [M+4H]4+: 704.7. 
 
3.4.2.  Peptide Synthesis 
 
All peptides were synthesized by solid phase peptide synthesis as C-
terminally amidated and N-terminally derivatives following standard Fmoc 
chemistry protocol on on a Fmoc-PAL-PEG-PS resin (0.18mmol/g). 
Cycles of coupling for each amino acid involves the following steps: 
 
 Deprotection   of the N-terminal function (2 step by 5 min) 
with a solution to a 30% Piperidine in DMF; 
 Coupling      of 2.5 equivalents of Fmoc-AA, 2.49 equivalents of 
HOBT/HBTU (0.45 M solution in DMF) and 3.5 equivalents of 
NMM compared with 0.05 mmol scale synthesis. The reaction 
time for each pair was 40 min; 
 Acetylation   two treatments of 5 min with the appropriate 
volume of a solution of Acetic anhydride (2M)/DIPEA 
(0.55M)/ DMF). 
 
After each module were performed three washes with DMF for 1min. 
Cleavage from the solid support was performed by treatment with a 
TFA/TIS/water (95:2,5:2,5, v/v/v) mixture for 3 hours at R.T. 
Crude peptides were analyzed   by analytical reverse phase HPLC apply-
ing a linear gradient of acetonitrile (0.1% TFA) from 5% to 50% in 30 min. 
at 0.8 mL/min. Peptide identities were confirmed by LC-MS system previ-
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ously described. A gradient of solvent B (0.05% TFA in CH3CN) from solvent 
A (0.05% TFA in H2O) of 5% to 50% was applied over 30 min.  
 
 
 
3.4.3. PNA-Peptide conjugates synthesis 
 
The synthesis of PNA-peptide conjugates was carried out in solid phase. 
The PNA oligomer was increased on PAL-PEG resin (0.18 mmol/g) function-
alized with the peptide, employing the same protocol described for the syn-
thesis of PNA 5 oligomer. The conjugates were cleaved by treatment with a 
solution of 78% TFA, m-cresol 20%, 2% TIS for 3 hours at room tempera-
ture. 
The PNA 5- TAT conjugate was analyzed by analytical RP-HPLC, applying a 
linear gradient of acetonitrile (0.1% TFA) (0.1% TFA) in water (0.1% TFA) 
from 5 to 50% in 30 minutes at 0.8 mL/min. The conjugate was purified by 
semi-preparative RP-HPLC, with the same gradient employed for analytical 
analysis and characterized by  LC-MS system previously described. A gradi-
ent of solvent B (0.05% TFA in CH3CN) from solvent A (0.05% TFA in H2O) of 
5% to 50% was applied over 30 min. 
 
 PNA 5-TAT (Da):  Calculated:  [M+3H]3+: 1549.4; [M+4H]4+: 1162.2;  
[M+5H]5+: 929.9; [M+6H]6+: 775.1;  
Found: [M+3H]3+: 1551.5; [M+4H]4+: 1163.8;  [M+5H]5+: 931.3; 
[M+6H]6+: 776.3. 
The PNA 5- NLS  conjugate was analyzed by analytical RP-HPLC, applying 
a linear gradient of acetonitrile (0.1% TFA) (0.1% TFA) in water (0.1% TFA) 
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from 5 to 50% in 30 minutes at 0.8 mL/min. The conjugate was purified by 
semi-preparative RP-HPLC, with the same gradient employed for analytical 
analysis and characterized by  LC-MS system previously described. A gradi-
ent of solvent B (0.05% TFA in CH3CN) from solvent A (0.05% TFA in H2O) of 
5% to 50% was applied over 30 min. 
 
 PNA 5-NLS (Da):  Calculated: [M+2H]2+: 1869.8; [M+3H]3+: 1246.8; 
[M+4H]4+: 935.4;  [M+5H]5+: 748.5; [M+6H]6+: 624.0; 
Found: [M+2H]2+: 1874.7; [M+3H]3+: 1251.3; [M+4H]4+: 938.5;  
[M+5H]5+: 751.2; [M+6H]6+: 626.1 
 
The NLS-PNA5- TAT conjugate was analyzed by analytical RP-HPLC, ap-
plying a linear gradient of acetonitrile (0.1% TFA) (0.1% TFA) in water 
(0.1% TFA) from 5 to 50% in 30 minutes at 0.8 mL/min. The conjugate was 
purified by semi-preparative RP-HPLC, with the same gradient employed for 
analytical analysis and characterized by LC-MS system previously described.  
A gradient of solvent B (0.05% TFA in CH3CN) from solvent A (0.05% TFA 
in H2O) of 5% to 50% was applied over 30 min. 
 
 NLS-PNA5-TAT (Da): Calculated: [M+3H]3+: 1837.9; [M+4H]4+: 1378.7;  
[M+5H]5+: 1103.2; [M+6H]6+: 919.1; [M+7H]7+: 788.2; [M+8H]8+: 
689.8. 
Found: [M+3H]3+: 1839.2; [M+4H]4+: 1379.6;  [M+5H]5+: 1103.9;   
[M+6H]6+: 920.1; [M+7H]7+: 788.8; [M+8H]8+: 690.3. 
 
 PNA 6- Bi-NLS conjugate was analyzed by analytical RP-HPLC, applying a 
linear gradient of acetonitrile (0.1% TFA) (0.1% TFA) in water (0.1% TFA) 
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from 5 to 50% in 30 minutes at 0.8 mL/min. The conjugate was purified by 
semi-preparative RP-HPLC, with the same gradient employed for analytical 
analysis and characterized by  LC-MS system previously described. A gradi-
ent of solvent B (0.05% TFA in CH3CN) from solvent A (0.05% TFA in H2O) of 
5% to 50% was applied over 30 min. 
 
 PNA 6- Bi-NLS (Da):  Calculated:  [M+3H]3+: 1968.0; [M+4H]4+: 1476.3;  
[M+5H]5+: 1181.2; [M+6H]6+: 984.5; [M+7H]7+: 844.0; [M+8H]8+: 
738.6; [M+9H]9+: 656.7; [M+10H]10+: 591.1;  
Found: [M+3H]3+: 1968.6; [M+4H]4+: 1476.7;  [M+5H]5+: 1181.6; 
[M+6H]6+: 984.8; [M+7H]7+: 844.3; [M+8H]8+: 738.9; [M+9H]9+: 657.0; 
[M+10H]10+: 591.4; 
 
 
 
3.4.4. PNA 5-TAT-NLS synthesis 
 
The synthesis of PNA 5-TAT conjugate was carried out in solid phase.  
The PNA oligomer was increased on PAL-PEG (0.18 mmol/g) resin function-
alized with the peptide, employing the same protocol described for the syn-
thesis of PNA oligomer unconjugated.  
Mtt group was removed employing several (15-20) short acidic treatment 
with a solution of DCM/TFA/ TIS (96.5/1/2.5 v/v/v) for 3 minutes. After 
each treatment  washes with DMF for 25s were performed.  A treatment 
with a solution to a 20% DIPEA in DMF for 5 min allowed the anchorage on 
TAT's side chain of the first amino acid of  NLS peptide. 
NLS was increased on PNA 5-TAT’s side chain, employing the same proto-
col described for the peptides synthesis. The conjugate was cleaved by 
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treatment with a solution of 78% TFA, m-cresol 20%, 2% TIS for 3 hours at 
room temperature. 
The PNA5- TAT-NLS  conjugate was analyzed by analytical RP-HPLC, ap-
plying a linear gradient of acetonitrile (0.1% TFA) (0.1% TFA) in water 
(0.1% TFA) from 5 to 50% in 30 minutes at 0.8 mL/min. The conjugate was 
purified by semi-preparative RP-HPLC, with the same gradient employed for 
analytical analysis and characterized by  MALDI-TOF Mass Spectrocopy. 
 
 PNA 5-TAT-NLS (Da):  Calculated: [M+H]+= 5550.02 m/z;  
                                                         Found: [M+H]+= 5456,25 m/z; 
 
3.4.5. FITC-PNA-Peptide conjugates synthesis 
 
The synthesis of PNAs-Peptide conjugates was carried out in solid phase. 
The PNA oligomer was increased on PAL-PEG (0.18 mmol/g) resin function-
alized with the peptide, employing the same protocol described for the syn-
thesis of PNA oligomer unconjugated.  
The introduction of  the linker was carried out in solid phase.  Fmoc-HAx-OH 
was added on PAL-PEG resin functionalized with the PNA-peptide conju-
gates, employing the same protocol described for the peptide synthesis, in-
volving the following steps:   
 
 Deprotection   of the N-terminal function (2 step by 5 min) 
with a solution to a 30% Piperidine in DMF; 
 Coupling of 2.5 equivalents of Fmoc-Hax-OH, 2.49 equivalents 
of HOBT/HBTU (0.45 M solution in DMF) and 3.5 equivalents 
of NMM compared with 0.05 mmol scale synthesis. The reac-
tion time for each pair was 40 min; 
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 Acetylation   two treatments of 5 min with the appropriate 
volume of a solution of Acetic anhydride (2M)/DIPEA 
(0.55M)/ DMF). 
Finally, after deprotection of N-terminal function with a solution to a 30% 
Piperidine in DMF, 5 equivalents  of FITC were added employing 7 equiva-
lents of NMM  and time reactions of 1h for each coupling steps.  To improve 
the coupling efficiency double couplings were carried out on each reagents. 
Conjugates were cleaved by treatment with a solution of 78% TFA, m-cresol 
20%, 2% TIS for 3 hours at room temperature. 
 
The FITC-PNA 5-TAT conjugate was analyzed by analytical RP-HPLC, ap-
plying a linear gradient of acetonitrile (0.1% TFA) (0.1% TFA) in water 
(0.1% TFA) from 5 to 50% in 30 minutes at 0.8 mL/min. The conjugate was 
purified by semi-preparative RP-HPLC, with the same gradient employed for 
analytical analysis and characterized by  LC-MS system previously de-
scribed. A gradient of solvent B (0.05% TFA in CH3CN) from solvent A 
(0.05% TFA in H2O) of 5% to 50% was applied over 30 min. 
 
 FITC-PNA5-TAT (Da):  Calculated: [M+3H]3+: 1716.1; [M+4H]4+: 
1287.3; [M+5H]5+: 1030.0; [M+6H]6+: 858.5; [M+7H]7+: 736.1; 
[M+8H]8+: 644.1. [M+9]9+: 572.7; [M+10]10+: 515.5. 
Found: [M+3H]3+: 1709.8; [M+4H]4+: 1282,6; [M+5H]5+: 1026.7; 
[M+6H]6+: 855.6; [M+7H]7+: 733.0; [M+8H]8+: 642.0. [M+9]9+: 570.3; 
[M+10]10+: 513.7. 
 
 
The FITC-PNA 6-Bi-NLS conjugate was analyzed by analytical RP-HPLC, 
applying a linear gradient of acetonitrile (0.1% TFA) (0.1% TFA) in water 
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(0.1% TFA) from 5 to 50% in 30 minutes at 0.8 mL/min. The conjugate was 
purified by semi-preparative RP-HPLC, with the same gradient employed for 
analytical analysis and characterized by LC-MS system previously described. 
A gradient of solvent B (0.05% TFA in CH3CN) from solvent A (0.05% TFA in 
H2O) of 5% to 50% was applied over 30 min. 
 
 FITC-PNA 6-Bi-NLS (Da):  Calculated: [M+4H]4+:1604.6; [M+5H]5+: 
1281.5; [M+6H]6+: 1068.1; [M+7H]7+: 915.7; [M+8H]8+: 801.3; 
[M+9H]9+: 712.7 
Found: [M+4H]4+:1601.6; [M+5H]5+: 1282.1; [M+6H]6+: 1068.6; 
[M+7H]7+: 916.1; [M+8H]8+: 801.3; [M+9H]9+: 712.4; 
 
 
The FITC-NLS-PNA5-TAT conjugate was analyzed by analytical RP-HPLC, 
applying a linear gradient of acetonitrile (0.1% TFA) (0.1% TFA) in water 
(0.1% TFA) from 5 to 50% in 30 minutes at 0.8 mL/min. The conjugate was 
purified by semi-preparative RP-HPLC, with the same gradient employed for 
analytical analysis and characterized by  LC-MS system previously de-
scribed. A gradient of solvent B (0.05% TFA in CH3CN) from solvent A 
(0.05% TFA in H2O) of 5% to 50% was applied over 30 min. 
 
 FITC-NLS-PNA 5-TAT (Da):  Calculated:  [M+4H]4+: 1504.6;  [M+5H]5+: 
1203.4; [M+6H]6+: 1003.1; [M+7H]7+: 859.9; [M+8H]8+: 752.5; [M+9]+9: 
669.0; [M+10H]10+: 602.2; [M+11H]11+: 547.6; [M+12H]12+: 502.0; 
[M+13]13+: 463.4. 
Found: :  [M+4H]4+: 1498.0;  [M+5H]5+: 1198.5; [M+6H]6+: 997.6; 
[M+7H]7+: 856.4; [M+8H]8+: 749.0; [M+9]+9: 665.7; [M+10H]10+: 599.0; 
[M+11H]11+: 544.3; [M+12H]12+: 499.7; [M+13]13+: 461.0. 
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3.4.6. Synthesis of TO-PNA 5-TAT conjugate 
 
3.3.6.a   Preparation of compound 1 (Figure 29) 
 
3-methylbenzothiazole-2-thione (2.00 g, 11.0 mmol, 1.00    
equiv.) and methyl iodide (3.00 g, 21.1 mmol, 1.92 equiv.)  
were combined in a 50 mL round bottom flask sealed 
with a rubber septa and heated to 45 °C for 5 hours. The reaction mixture 
became a white solid. After cooling to 25 °C, the solid was resuspended in 
100 mL methanol. Diethyl ether (75 ml) was added to ensure that the prod-
uct had fully precipitated. The precipitate was collected by vacuum filtration 
and dried under reduced pressure to yield 2.74 g (77%) of a white solid. UV-
Vis: max (H2O): 226 nm (= 24,700 M-1cm-1), 306 nm (= 17,200 M-1cm-1); 1H 
NMR (400 MHz, DMSO) d 3.13 (s, 3H, SCH3), 4.12 (s, 3H, NCH3), 7.73 (m, 1H, 
Ar), 7.85 (m, 1H, Ar), 8.20 (d, J= 8.42 Hz, 1H, Ar), 8.40 (d, J= 8.42 Hz, 1H, Ar);  
 
 
3.3.6.b  Preparation of compound 2 (Figure 29) 
 
Lepidine (2.21 g, 15.5 mmol, 1.00 equiv.) 
and 6-bromohexanoic acid (3.29 g, 16.9 
mmol, 1.09 equiv.) were combined in a 100 
mL round bottom flask sealed with a  rubber 
septa and heated at 125 °C for 5 hours.  
The resulting brown residue was dissolved in 28 mL of methylene chloride 
and the product was precipitated upon addition of 16 mL of acetone. The 
precipitate was collected by vacuum filtration and dried under reduced 
pressure to yield 2.87 g (55%) of a tan solid. UV-Vis: max (H2O) 234 nm (= 
33,200 M-1cm-1), 314 nm (= 8,300 M-1cm-1); 1H NMR (400 MHz, DMSO) d 
S
N+
S
I-
N+
OH
O
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1.40 (m, 2H, CH2), 1.56 (m, 2H, CH2), 1.96 (m, 2H, CH2), 2.23 (t, J= 7.2 Hz, 2H, 
CH2), 3.01 (s, 3H, CH3), 5.01 (t, J= 7.5 Hz, 2H, NCH2), 8.07 (m, 2H, Ar), 8.27 
(m, 1H, Ar), 8.58 (m, 2H, Ar), 9.42 (d, J= 5.85 Hz, 1H, Ar); 
 
3.3.6.c  Preparation of compound 3 (Figure 29) 
 
Compound 1 (1.21 g, 3.58 mmol, 1.00 
equiv.) and compound 2 (1.16 g, 3.58 mmol, 
1.00 equiv.) were suspended in 36 mL of 
ethanol and heated to 70 °C for 1 hour to 
dissolve.  
Triethylamine (1.10 mL, 7.82 mmol, 2.18 equiv.) was then added and the re-
action was cooled to 50 OC. After 3 hours, the slurry was allowed to cool to 
25 °C, and diethyl ether (107 mL) was added to fully precipitate a red solid. 
The crude solid was suspended in acetone (70 mL)/ ether (100 mL) for 1 
hour, collected by vacuum filtration and dried under reduced pressure to 
yield 1.06 g (56%) of a red solid. UV-Vis: max (H2O) 502 nm (= 66400 M-
1cm-1); 1H NMR (400 MHz, DMSO) d 1.38 (m, 2H, CH2), 1.56 (m, 2H, CH2), 
1.86 (m, 2H, CH2), 2.21 (t, J= 7.2 Hz, 2H, CH2), 4.03 (s, 3H, NCH3), 4.61 (t, J= 
7.2 Hz, 2H, NCH2), 6.94 (s, 1H, CH), 7.40 (m, 2H, Ar), 7.62 (m, 1H, Ar), 7.77 
(m, 2H, Ar), 8.00 (m, 1H, Ar), 8.07 (d, J= 4 7.69 Hz, 1H, Ar), 8.15 (d, J= 9.16 
Hz, 1H, Ar), 8.65 (d, J= 6.96 Hz, 1H, Ar), 8.81 (d, J= 8.62 Hz, 1H, Ar); 13C NMR 
(125 MHz, DMSO): d 175.6, 161.2, 149.7, 145.6, 141.7, 138.2, 134.5, 129.4, 
128.0, 127.0, 126.0, 125.4, 125.1, 124.1, 119.3, 114.2, 109.0, 89.3, 55.2, 35.1, 
34.9, 29.8, 26.7, 25.3; 
 
  
 
 
N+
NS
OH
O
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3.3.6.d  Preparation of TO-peptide conjugates (Figure 29) 
 
 
TO-PNA5-TAT conjugate  was synthesized on solid support using com-
mercially available Fmoc-PAL-PEG-PS (0.18 mmol/g). The TO was increased 
on PAL-PEG (0.18 mmol/g) resin functionalized with the PNA 5-TAT conju-
gate, employing the following protocol: 
 
 Deprotection of the N-terminal function (2 step by 5 min) with 
a solution to a 30% Piperidine in DMF; 
 Coupling of 2.5 equivalents of TO, 2.49 equivalents of 
HOBT/HBTU (0.45 M solution in DMF) and 3.5 equivalents of 
NMM compared with 2 mol scale synthesis. The reaction time 
for each pair was  1h; 
 Acetylation   two treatments of 5 min with the appropriate 
volume of a solution of Acetic anhydride (2M)/DIPEA (0.55M)/ 
DMF). 
The conjugates were cleaved by treatment with a solution of 78% TFA, m-
cresol 20%, 2% TIS for 3 hours at room temperature. 
TO-PNA5-TAT purification was carried out by semi-preparative RP-HPLC 
applying a linear gradient of acetonitrile (0.1% TFA) from 5% to50% in 30 
min. 5 mL/min. PNA 5 purity and identity were confirmed by LC-MS system 
previously described; A gradient of solvent B (0.05% TFA in CH3CN) from 
solvent A (0.05% TFA in H2O) of 5% to 70% was applied over 30 min. and it 
was identified by electrospray mass analysis. 
 
 TO-PNA5-TAT (Da):  Calculated: [M+3H]3+: 1678.3; [M+4H]4+: 1259.1;  
[M+5H]5+: 1007.6; [M+6H]6+: 839.6; [M+7H]7+: 719.8; [M+8H]8+: 
630.1; [M+9H]9+: 560.1. 
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 Found: : [M+3H]3+: 1676.2; [M+4H]4+: 1257.4;  [M+5H]5+: 1006.2; 
[M+6H]6+: 838.6; [M+7H]7+: 718.9; [M+8H]8+: 629.6; [M+9H]9+: 559.7. 
 
3.4.7. TO-PNA 5-TAT strand invasion and fluorescence measurement  
 
DNA5-DNA5c duplex was obtained employing 1M of DNA 5 and 1M of 
DNA 5c in buffered solution (100 mM NaCl, 10 mM NaH2PO4, pH 7.0). After 
annealing reaction (90° C 5 min, 4°C over night), strand invasion experi-
ments using TO-PNA 5-TAT were performed, adding : a) 1M of probe to 
duplex solution (TO-PNA 5-TAT: DNA5/DNA5c ratios was 1:1); b) 2M of 
probe to duplex solution (TO-PNA 5-TAT: DNA5/DNA5c ratios was 2:1);  
 Fluorescence measurements were carried out in buffered solution (100 
mM NaCl, 10 mM NaH2PO4, pH 7.0), employing 1M oligos and probes in a 
final volume of 2.5 mL (ex=470 nm, slitex = 2.5, slitem= 10.0).  
The DNA sequences were:  
5-CAGGGCAGCCCCTGCCCACCGCACACTGCGCTGCACGTACGT-3’ (DNA5) and 
5’-CCAGACCCACTGTGCGTGTGACAGCGGCTGATCTG-3’ (DNA5c).   
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CHAPTER 4 
 
 
4. SECOND GENERATION PNA 
 
The success of PNAs unveiled that oligonucleotide analogs could be ob-
tained with drastic changes from the natural structure, provided that some 
important structural features were preserved. The PNAs scaffold has served 
as a model for the design of new compounds able to perform DNA recogni-
tion117. 
Synthetic organic chemistry has played a fundamental role in the 
achievement of these goals, by allowing to obtain new structures for the PNA 
monomers, and by developing novel strategies for oligomer synthesis (Fig-
ure 37). Since their discovery many modifications of PNA structures have 
been proposed, in order to improve their performances in term of affinity 
and specificity towards complementary oligonucleotides. A modification in-
troduced in the PNAs structure can improve its pharmacological potential 
generally in three different ways: i) improving DNA binding affinity; ii) im-
proving sequence specificity, in particular for directional preference (anti-
parallel vs parallel) and mismatch recognition118; iii) improving bioavailabil-
ity (cell internalization, pharmacokinetics, etc.). 
This area of research has been particularly active and the recent literature is 
full of publications that describe the synthesis and properties of new ana-
logues of PNA119.  
Modified nucleotide bases can be used to interfere in the processes of hy-
bridization (Figure 38). 
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Figure 37: PNA structural modifications 
 
For example, a N4-benzoyl cytosine (1) is able to inhibit the formation of 
the triplex (PNA)2/DNA as it creates steric hindrance reason120. The base 
pair 2-thiouracil (2) and 2.6-diamminopurina (3) acts on the recognition be-
tween PNA and DNA with a peculiar mechanism known as double-duplex 
invasion leading to the formation of the complex with stoichiometry (PNA)2-
(DNA)2121. The replacement of cytosine with 5-methylcytosine (4) in a PNA-
DNA chimera increases the stability of the duplex, while the replacement of 
thymine with 5 - bromouracil (5) has no effect in terms of increased or de-
creased stability.  Instead, the simultaneous introduction of two modified 
bases 4 and 5 in a PNA-DNA chimera causes a destabilization of the triple 
helix (DNA)2/PNA-DNA, if compared to a  DNA triplex122. 
 
 
 
 
 
 
 
Figure 38:  Examples of modified nucleobases. 
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Modifications in the linker have underlined the importance of the methyl-
ene carbonyl group for the structural organization of a PNA oligomer and  
the hybridization process. In fact, the replacement of these with both rigid 
and flexible linker led always to a duplex destabilization.  A devastating ef-
fect on the binding properties of PNA was observed with the conversion of 
the tertiary amide bond in the corresponding tertiary amine76 (Figure 39).  
 
 
 
 
 
 
 
Figure 39: Replacement of the methylene carbonyl linker with a more flexible ethylene 
linker 
 
 
 
4.1.     CHEMICAL MODIFICATION OF PNA BACKBONE 
 
Introduction of different functional groups with different charges/ flexi-
bility/polarity in the backbone have been described119a,123-124 and these 
study showed that a “constrained flexibility” is necessary to have a good 
DNA binding. On the basis of these studies, modified PNAs have been con-
stantly improved during the years, using the concept of “preorganization”, 
i.e. the ability of adopt a conformation suitable for DNA binding, thus mini-
mizing the entropy loss of the binding process. 
Figure 40 shows the main strategies used to achieve this goal. Preorgani-
zation was obtained either by cyclization of the PNA backbone (in the ami-
noethyl side or in glycine side), by adding substituents in the C2 position) 
N
H
N
O
B
93 
 
or C5 position) carbon of the monomer or by inserting the aminoethyl 
group in cyclic structures125. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 40: Strategies for inducing preorganization in the PNA monomers. 
 
The two classes of PNA with conformationally constrained backbones 
which have shown improved properties are acyclic PNAs with functional 
backbones and cyclic PNAs, in which preorganization is achieved through 
conformational constraint or through rigidification of the backbone. 
In the following paragraphs the classes of acyclic PNAs will be discussed in 
details. 
 
4.1.1. ACYCLIC PNAS WITH CONSTRAINED STRUCTURES 
 
In 1994, Nielsen and co-workers showed how the insertion of a methyl-
ene group in any position of the PNA backbone or in the linker between the 
backbone and the nucleobase resulted in a net loss of DNA binding proper-
ties. This fact was subsequently explained in terms of “constrained flexibil-
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ity” of PNAs: in order to be a good DNA binding molecule, a modified oli-
gonucleotide should not be too flexible,  nor too rigid. 
Using the linear N-(2-aminoethyl)glycine as starting point, several PNA 
derivatives were obtained by insertion of side chain either at the Cor 
Ccarbon atoms126. These modifications could modulate the conformational 
properties of PNA. Nielsen at al., starting from L-amino acid synthons, syn-
thesized C-substituted chiral PNAs and showed that the insertion of an 
amino acid derived side chain slightly destabilized antiparallel PNA-DNA 
duplexes. Chiral PNAs derived from alanine or from arginine and lysine side 
chains showed the best affinity for DNA, on account, respectively, of the 
small steric hindrance and of the electrostatic interaction with the nega-
tively charged DNA strand. Instead PNAs bearing side chains derived from 
bulky apolar amino acids (valine, tryptophan or phenylalanine) displayed a 
bad affinity for DNA. These data clearly showed that the steric hindrance is 
responsible for the destabilization of  PNA / DNA duplexes. 
The affinity of chiral PNAs  for complementary DNA  was found to be also 
influenced by the enantioselectivity. In absence of any stereogenic centers, 
two achiral complementary PNAs will form an equimolar mixtures of left-
handed and right-handed helices. Instead, the addition of  some stereogenic 
centers in one of the PNA strands, leads to the predominance of an orienta-
tion of the helices127. 
On the basis of such premises, Sforza and colleagues have synthesized 
PNAs containing a chiral D-lysine and by X-ray diffraction they showed that 
D-configuration allows the lysine side chains to be placed in an optimal posi-
tion to fit in right-handed helix, whereas the L-lysine side chains would have 
given strong intra-strand steric clashes128. 
These studies were further confirmed by Nielsen and colleagues (creating 
PNA monomers substituted in  position by D lysine) and  by Ly and co-
workers (they developed cell-penetrating arginine PNAs). 
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In conclusion the use of several C-substituited lysine-based monomers 
inserted in a PNA strand allows to prevent self-aggregation of complemen-
tary PNA sequences, while increasing the affinity for negatively charged 
DNA129. However only a few such modifications showed improvements in 
the hybridization properties, many of which require either elaborate syn-
thesis or the use of relatively expensive D-amino acids as starting materials 
(because L-configuration in  position does not allow to bind to DNA or 
RNA).  
For these reasons gamma Peptide Nucleic Acid have been recently inves-
tigated. A detailed study was performed by Sforza et al. by comparing chiral 
PNAs substituted with L- or D-lysine at either  and  position or at both po-
sition simultaneously130.  They confirmed that PNAs derived from L-amino 
acids adopted a right-handed helix and they are able to hybridize to DNA 
and RNA with high affinity and sequence selectivity128. Starting from these 
considerations, modifications  at position seems to be the most promising 
because of the simplicity and flexibility in synthesis and the benefits that 
they confer on the hybridization properties of PNA. Several analogues have 
been explored so far, having methyl, hydroxymethyl, thiomethyl, aminobutyl 
and guanidinium groups131, 132 (Figure 41). 
 
 
 
 
 
 
 
 
 
 
Figure 41: -modified PNA analogues 
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The introduction of a side chain in the position does not compromise 
DNA binding. For example, functionalization of the position with a  bu-
tylamino group, such to mimic the lysine  side chain, not only does not affect 
the formation of PNA/DNA duplex, but also leads to a slight increase in 
thermal stability of the complex formed. Moreover, these features are pre-
served even if the amino group of the lysine side chain is further functional-
ized  with quite bulky molecules, such as fluorophores133.  
Rapireddy et al. showed that GPNA, PNA analogues with a guanidine 
group on the α position of the backbone, designed to target the transcrip-
tional start-site of the E-cadherin gene were demonstrated to effectively in-
hibit protein translation, showing low toxicity and high cell permeability119a. 
These analogues were found unable to inhibit gene transcription, probably 
due to electrostatic interactions with the phosphates of nucleic acids which 
slow down the diffusion of the molecules in the cytoplasm and in the nu-
cleus. Sahu and colleagues have proposed instead a second generation of 
GPNA arising from L-amino acids and in which the guanidinium group is lo-
cated in gamma position134. These derivatives have shown favorable proper-
ties of hybridization as well as cellular uptake. 
Recently Crawford et al. have shown that the substitution at the-position 
of a number of amino acid side chains with varying degree of steric hin-
drance (valine, isoleucine, phenylalanine, alanine) does not affect the hy-
bridization properties of PNAs135.  
Studies on  PNA oligomers demonstrated that preorganization is a requisite 
to increase the affinity of binding toward complementary nucleic acids while 
the presence of positive charges on the backbone increases their cellular up-
take. CD studies on PNA oligomers containing  hydroxymethyl have shown 
that these oligomers are structurally preorganized131c; The secondary struc-
ture of the oligomers depends on the position of the chiral moiety and is in-
duced when the chiral moiety is at the C-terminus. Recently the crystal 
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structure of a γ PNA/DNA duplex has been solved; these studies revealed 
that the helix is induced by the steric clash between the  carbon and the ni-
trogen of the tertiary amide of the backbone and is stabilized by the sequen-
tial base stacking136. 
Interestingly the stability of the hybrids is not influenced by the spacing 
between the chiral units. Furthermore  PNA are the only analogue discov-
ered so far having the ability to invade a mixed sequence DNA double 
helix131d, 137. The ease and flexibility of synthesis, along with superior hy-
bridization properties and enzymatic stability, make PNAs an attractive nu-
cleic acid platform for various biological and medical applications- as mo-
lecular tools as well as therapeutic and diagnostic reagents. 
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4.2. RESULTS AND DISCUSSION 
 
4.2.1. SYNTHESIS AND CHARACTERIZATION OF  SULPHATE PNAS 
 
Encouraged by these results reported in the literature on  PNA and with 
the aim to develop a new PNA analogue more DNA-like in terms of polarity, 
charge and solubility we undertook studies on PNAs having a sulphate 
moiety in the gamma position of the backbone. Studies on  sulphate PNA  
add a new brick to our knowledge on the effect of charge on the secondary 
structure, stability of the hybrids and potential of the modified oligomer to 
be biologically active.  
The sulphate group is, in fact, very similar to the phosphate of DNA, in ge-
ometry, steric hindrance, polarity; furthermore a sulphate monoester has 
the same charge as the phosphate diester present in oligonucleotides. The 
sulphate PNA should in principle keeps the advantages of standard PNA 
(stability to degradation and binding affinity) and also should be more solu-
ble, less prone to aggregation. Two more advantages of this negatively 
charged analogue are: 1) the possibility to increase its uptake employing the 
tools commonly used for DNA transfection138 . In fact PNA and PNA ana-
logues (with the only exception of guanidine PNA134), although showing 
high binding affinity towards natural nucleic acids and high stability to en-
zymatic degradation, do not easily cross the cell membrane and conse-
quently show weak biological activity (the delivery of PNA by lipofectamine 
or other cationic lipids employed for the common DNA delivery has been 
demonstrated only for PNA complexed to DNA or PNA conjugated to nega-
tively charged peptides77, 139). 2) the lack of unspecific interactions with nu-
cleic acids, which instead may occur with positively charged PNA analogues, 
as the  guanidine PNA.  
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In this work  sulphate PNAs were investigated, setting up protocols for 
the synthesis of  sulphate PNA monomers and oligomers. PNA  sulphate 
monomers were obtained after derivatization of -hydroxymethyl mono-
mers, synthesized employing  a modified version of the protocol reported in 
the literature for  Ser PNA starting from L-Fmoc-Ser(OtBu)-OH131c (Figure  
42).  
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Figure 42: Strategy for functionalized backbone synthesis 
 
The amino acid was converted into the corresponding amide by reaction 
with N,O-dimethylhydroxylamine hydrochloride, in presence of DMAP, 
TEA, and EDC as activator. The product was purified by extraction with HCl, 
NaHCO3 acq. and 10% H2O and finally chromatographed on silica gel. The re-
action proceeds with high yields. The reduction of the amide function with 
lithium aluminum hydride in Et2O gives the corresponding aldehyde, isolated 
after extraction with ethyl ether and water with a quantitative yield. Finally, 
the aldehyde was subjected to reductive amination with glycine methyl ester 
and DIPEA, thus generating the modified backbone. 
The functionalization of the bases, involved the anchorage to N 1 of the 
pyrimidines (C, T) or the N 9 of purines (G, A) of a methylene carbonyl group, 
essential in order to react with the amino group in   position of glycine . 
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First of all the bases that possess the exocyclic NH2 should be properly pro-
tected;  the choice of protecting groups for exocyclic amino functions and the 
terminal amino function of the backbone falls to  orthogonal protecting 
groups.  In the monomers the exocyclic amines of the nucleobases A, C and G 
are protected with base labile groups (benzoyl for A and C, isobutyryl for G, 
Figure 43)140.  
 
 
 
 
 
 
 
Figure 43: Protected Bases 
 
  The functionalization of the four nucleobases has been achieved through a 
strategy described in the literature that involves the introduction of the  me-
thylene carbonyl linker employing methyl-bromoacetate in DMF for thymine 
and guanine, tert-butyl-bromoacetate in DMF for adenine and benzyl bro-
moacetate for cytosine. 
The products were purified by filtration or  liquid chromatography on sil-
ica gel. The modified backbone was used for the coupling reaction with the 
derivatized bases (Figure 44) employing DMAP and EDC. 
In order to use these modified monomers in the solid-phase synthesis, it was 
necessary to remove the ester function on the carboxyl group by a very 
strong basic hydrolysis, which caused also the removal of the Fmoc protect-
ing group, successively reintroduced employing Fmoc-OSu and  sodium bi-
carbonate. 
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Finally, after removing under mild acid condition tert-butyl group on -
hydroxymethyl function, the sulphate was installed on the hydroxyl after re-
action with the DMF∙SO3 complex and treatment with TBA/NaHCO3. 
 
 
 
 
 
 
 
. 
Figure 44: strategy for  sulfate monomers 
TBA acts as a counterion to stabilize the sulfate group, which otherwise 
would be acid labile, thus making this molecule not compatible with the reac-
tion conditions used in solid-phase synthesis. The stability of the sulphate to 
both acidic and basic conditions was verified in two separate experiments 
carried out treating the tS monomer with the cleavage and deprotection so-
lutions, respectively a concentrated TFA solution for 2 hours at room tem-
perature and a concentrated ammonia solution at 50°C for 16 hours141 (data 
not shown). The reactions were monitored by LC-MS; except for the removal 
of the Fmoc group occurring in basic conditions, no other reaction was ob-
served, demonstrating thus that the TBA counterion is sufficient to stabilize 
the sulphate group.  All monomers were characterized by electrospray mass 
analysis and NMR (Figure 45). 
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Figure 45: mass spectra of modified monomers 
 
We performed NMR experiments on Fmoc-PNA OH and Fmoc- PNAS  
monomers dissolved in DMSO142. The discussion is limited to the guanine 
monomer but the spectral features described were also observed for the 
other monomers. An expansion of the backbone region of the 2D-TOCSY143 
for the two guanine monomers (gOH in red and gS in blue) is reported in Fig-
ure 46.  
NMR studies reveal that all monomers exist  as a mixture of two rotamers, 
due to the rotation around the C7-N4 bond, with rotamer A being the most 
abundant. 
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Figure 46: superimposition of  the 2D-TOCSY , expansion of the backbone region, for the 
gS and gOH monomers. 
 
As expected 1H NMR signals of the backbone shift downfield upon introduc-
tion of the sulphate on the C2 hydroxymethyl (Table 5). 
protons 
gS 
rotamer 
A 
gS 
rotamer 
B 
gOH 
rotamer 
A 
gOH 
rotamer 
B 
1 7.53 7.32 7.43 7.12 
2 4.04 3.85 3.90 3.67 
3a 3.69 3.47 3.49 3.33 
3b 3.39 3.21 3.37 3.16 
9 3.87 3.71 3.67 3.57 
Table 5: 1H chemical shift for the gS and gOH backbone protons. 
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The NOESY spectrum has been used to determine the geometry of the ter-
tiary amide bond: a NOE144 cross-correlation peak between H-8 and H-3 is 
found in the conformation where the carbonyl C-7 points toward the C ter-
minus (rotamer A), while a NOE cross-correlation peak between H-8 and H-
5 where C-7 carbonyl group points toward the N terminus (rotamer B) (Fig-
ure 47). A clear difference is evident between the two monomers: the signals 
for rotamer A and B of the Fmoc-gOH-OH monomer have a comparable in-
tensity while in the Fmoc-gS-OH monomer the signals of rotamer A have 
about two times the intensity of those of rotamer B.  
This indicates that in the Fmoc-gS-OH monomer  the conformation in 
which the C-7 carbonyl group points toward the C-terminus is slightly fa-
voured.  modified PNA monomers show different conformational prefer-
ences depending on the steric hindrance of the substituent on C2. To gain de-
tails on the structural preferences of sulphate PNA monomers, studies were 
performed to  identify and evaluate the coupling pattern of the spin system 
composed of H-2, H-3a, H-3b by a DQ-COSY experiment carried out on the 
sulphate guanine monomer (gs). The signal of H-3a for rotamer A appears as 
doublet of doublets with coupling constants of  15  and 10 Hz, while H-3b 
appears as a doublet of doublets with coupling constants of 15 and 5 Hz. 
(Figure 47).  
This suggests the presence of a preferred conformation in solution that 
involves one trans diaxial interaction (180°)  between H-2 and H-3a (J of 10 
Hz) and one axial to equatorial interaction (+60°) between H-2 and H-3b (J 
of 5 Hz). 
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Figure 47 :  the two hypothesized conformations for the gS monomers. 
The 15 Hz coupling constant corresponds to the geminal coupling (J2) 
between H-3a and H-3b. For rotamer B we observe a ∼10 Hz coupling con-
stant between H-3b and H-2 corresponding to a trans diaxial relationship, 
and a ∼5 Hz coupling constant between H-3a and H-2 corresponding to an 
equatorial to axial relationship (Figure 48). Being R the absolute configura-
tion at C-2, the conformation that produces the relative spatial arrangement 
of protons H-2, H-3a, and H-3b in rotamer A corresponds to that observed in 
PNA monomers when they are in oligomers forming a right-handed helix.  
The conformation of  rotamer B corresponds to an extended conforma-
tion. These data suggest that the introduction of a sulphate in the gamma 
position of the backbone partially modifies the conformational preferences 
of  modified hindered monomers. Interestingly, the conformation of ro-
tamer A reproduces the situation observed in valine and isoleucine 
modified monomers136. The restricted rotation around C2-C3 forces the 
monomer in a specific conformation, corresponding to the one adopted in a 
right handed helix. On the other hand, rotamer B, assumes a more extended 
conformation, as demonstrated by the inversion in the pattern of coupling 
constants. 
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The next step was to set up experimental conditions for the solid phase 
coupling  for all four monomers. A series of mixtures of activator and bases 
were tested. The best coupling conditions result to be the following. 
For Fmoc- tS-OH: 50 µL of a 0.3M solution  (7.9 eq.) in an. DMF of monomer, 
50 µL of HBTU (0.2M) (5.2 eq.) in DMF, 50 µL MDCH (0.8M) in pyridine, 30 
minutes. For Fmoc- cS (Bz)-OH, Fmoc-aS (Bz)-OH, Fmoc gS (iBu)-OH: 50 µL  of 
a 0.3M solution  (7.9 eq.) in an. DMF of monomer, 50 µL  of HBTU (0.2M) (5.2 
eq.) in DMF, NMM 0.2M, 50 µL  of pyridine 0.2M in DMF , 30 minutes.  
To target the ErbB2 gene promoter, the sequence CTCCTCCTC, encompass-
ing tract from -220 to -228 upstream of the first codon, was chosen141a-146.   
In the sequence all T were inserted as sulphate T (tS). Studies were fo-
cused on a homopyrimidine oligomer designed to interfere with the tran-
scription of the gene ErbB2, a cell membrane surface-bound receptor tyro-
sine kinase normally involved in the signal transduction pathways leading to 
cell growth and differentiation. ErbB2 is encoded within the genome by 
Her2/neu, a known proto-oncogene of great importance for its involvement 
in breast cancer development and its correlation to increased chemoresis-
tance of the cancer cells145, 146. 
The oligomer ctScctScctSc (PNA7 S) was assembled on a PAL-PEG resin us-
ing standard conditions for the standard monomers147 and the conditions 
described earlier for the tS building blocks. The oligomer was cleaved in 
standard conditions, purified by RP-HPLC and characterized by LC-MS (Fig-
ure 48). 
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Figure 48: HPLC profile and ESI for PNA7 S. 
The unmodified PNA ctcctcctc (PNA 7) was obtained using the previously 
showed protocols 116,  purified by RP-HPLC, characterized by electrospray 
and used in the control experiments. 
The oligomer containing hydroxymethyl modified  PNA T monomer (tOH), c 
tOHcctOHcctOHc (PNA7 OH) was obtained as the ctScctScctSc, the tOH monomer 
was coupled as the tS monomer and used in the control experiments. 
Studies on the secondary structure of a polypirimidine oligomer were car-
ried out by CD.  
CD spectra of the oligomer ctScctScctSc (PNA7 S) were recorded at differ-
ent concentrations. A very weak signal appears when the oligomer has a 
10M concentration; the CD spectrum shows a deep minimum at 267 nm 
and a very shallow minimum at 238 nm. The CD spectrum of PNA7 S was 
compared to that of PNA7 OH, the analogue oligomer containing tOH mono-
mers (Figure 49).  
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Figure 49: CD spectra  of PNA7 S ( _ ) and PNA7 OH (---) in 10mM Phosphate buffer, pH 7 
at 10mM strand concentration. 
 
It is reported in the literature that PNA oligomers containing gamma hy-
droxymethyl monomers adopt the structure of a right handed helix131c. The 
spectra recorded for PNA7 S and PNA7 OH show bands in the same position, 
with the bands in PNA7 S spectrum being far less intense. This result sug-
gests that the PNA7 S oligomer has a lower content of secondary structure 
as compared to the PNA7 OH oligomer. Likely this reflects the presence of a 
population of monomers which assume an extended conformation, as as-
sessed by NMR,  and do not induce any secondary structure in the oligomer.  
 Furthermore it is also reasonable to hypothesize that the electrostatic re-
pulsions between the negative charges and the steric hindrance of sulphates 
in the backbone contribute to the helix unwinding in PNA7 S. Polypirimidine 
PNA sequences are known to hybridize DNA forming triplexes of 
stoichiometry PNA2/DNA.  
In order to determine the stoichiometry of the polypirimidine 
PNA7S/DNAc complex (DNAc, complementary sequence, GTGGTGGTG), the 
continuous variation method was employed. The absorbance at 260 nm of 
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PNA7 S (and PNA7) and DNAc solutions at different PNA7 S (PNA7)/DNAc 
ratios was measured. The plots of the absorbance vs the molar fraction of the 
PNA7 S (PNA7) show in both cases a minimum around 0.7, which suggests a 
stoichiometry 2:1 PNA7 S (PNA7):DNAc (Figure 50).  
 
 
Figure 50: Job Plot for stoirchiometric determination of (PNA7 S)2/DNAc complex . 
 
The presence of sulphates in the side chain of the oligomer PNA7 S does 
not hamper the formation of hybrids with complementary DNAc; the 
stoichiometry of the hybrid suggests that PNA7 S follows the same hybridi-
zation rule as standard PNA7. 
The structure of the triplexes formed by PNA7 S with complementary 
DNAc was also investigated by CD and compared to the structure of a triplex 
formed by the unmodified PNA7 oligomer. CD spectra for the two hybrids 
are superimposable, showing two maxima at 270 and 225 nm and one 
minimum at 250 nm (Figure 51). The spectrum recorded for the DNA tri-
plex, as expected, is different. PNA7 S forms a triple helix having the features 
of the P-helix formed by standard PNA148.  
110 
 
 
Figure 51: CD spectra of (PNA7 S)2/DNAc (_), and (PNA 7)2/DNAc (--) in 10mM Na buffer, 
100mM NaCl, 5mM MgCl2, Ph 7 at 3M triplex concentration. 
 
 
The stability of the hybrid was investigated by melting experiments fol-
lowed by CD. Melting curves were recorded for the (PNA7 S)2DNAc and, as a 
control, for the  (PNA7)2DNAc and for the (DNA)2DNAc triplexes  (see Table 
6 for the  sequences of the oligomers). 
Name sequence number 
PNA7  S ctSc ctSc ctSc 1 
PNA7 ctcctcctc 2 
PNA7  OH ctOHc ctOHc ctOHc 3 
DNA CTCCTCCTC 4 
DNAc GAGGAGGAG 5 
DNA c mis GAGCAGGAG 6 
DNA c mis S GAGGTGGAG 7 
Table 6 : Oligomers sequences. PNA bases are indicated with lower case letters, DNA 
bases with upper case letters. 
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In all cases a single transition was observed. The Tms were estimated to be 
52.2 °C for (PNA7)2DNAc,  46.6°C for (PNA7 S)2DNAc  and 42.2  for 
(DNA)2DNAc  (Table 7).  
triplex (1)25 (1)26 (1)27 (2)25 (2)27 (4)25 (4)27 (1)25 * 
Tm 46.6 29.6 24.2 52.2 32,5 42.2 26.8 50,8 
Table 7: melting temperature of the triplexes recorded in 10mM Na Phosphate buffer, 
100mM NaCl, 5mM MgCl2, pH 7 ; * higher ionic strenght:  10mM Na Phosphate buffer, 
200mM NaCl, 10mM MgCl2, pH 7.  
 
The PNA7 S triplex is thermally more stable than  the DNA triplex. How-
ever a destabilization with respect to the standard PNA7 hybrid is observed, 
which can be explained considering the electrostatic repulsion between the 
negatively charged phosphate of DNA and sulphate of PNA7 S. The effect of 
the introduction of one mismatch in the complementary DNA strand on the 
melting temperature of the hybrids was investigated in two cases: when the 
mismatched base is complementary to a PNA monomer in PNA7 S (DNA mis: 
GAGCAGGAG) and when the mismatched base is complementary to a tS 
monomer (DNAc mis S: GAGGTGGAG).  
A significant decrease in the melting temperature of the triplex was ob-
served in both cases, being larger (-22.4°C) for the latter, demonstrating 
thus the high selectivity in the binding of sulphate modified PNAs. In parallel 
the same effect was investigated on hybrids formed by PNA7 and DNA oli-
gomers measuring their melting temperature. The triplexes (DNA)2DNA mis 
S and (PNA7)2DNA mis S have a melting temperature respectively 15.4 °C 
and 19.7°C lower than  the perfectly matched hybrid. The effect of a single 
mismatch on the melting temperature of the hybrid formed by PNA7 S sug-
gests it has the highest selectivity in the binding of DNA as compared to 
PNA7 and DNA. Furthermore, as the thermal stability of DNA hybrids de-
pends on the ionic strength, unlike that of hybrids formed by standard 
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PNA7149, being increased  at high ionic strength, we investigated the effect of 
the ionic strength on the stability of the PNA7 S hybrid. The melting tem-
perature of (PNA7 S)2 DNA was found dependent  by the ionic strength,  be-
ing increased of about 4°C when the concentrations of NaCl and MgCl2 are 
doubled. 
To evaluate the effect of sulphate PNA on gene expression, the ErbB2 gene 
targeting was chosen as model. ErbB2 is a known proto-oncogene localized 
on the long arm of chromosome 17 (17q11-21). Its over-expression has 
been reported in numerous cancers, including breast and ovarian tumors 
and  is correlated to increased chemoresistance of the cancer cells146.  
ErbB2 encodes a protein member of the EGFR/erbB protein family, more 
commonly known as the epidermal growth factor receptor family. ErbB2 is a 
cell membrane surface-bound receptor tyrosine kinase  which is normally 
involved in the signal transduction pathways leading to cell growth and dif-
ferentiation145. EGFR signaling is activated by non specific ligand binding to 
the extracellular domain of the receptor. This determines receptor homo-
/hetero-dimerization and a subsequent autophosphorylation by the intra-
cellular kinase domain, resulting in receptor activation. After activation, 
phosphorylation of cytoplasmic substrates occurs and a signaling cascade 
drives many cellular responses, which include changes in gene expression, 
cytoskeletal rearrangement, anti-apoptosis and increased cell 
proliferation150.  
4.2.2. CYTOTOXICITY ASSAY 
 
A cytotoxicity assay on SKBR3 with increasing concentrations of PNA7 S 
was performed. Results showed no significant difference on cell survival 
with respect to SKBR3 grown in the absence of the oligonucleotide ana-
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logues (data not shown). Thus, these data demonstrates that there is no in-
trinsic toxicity of the sulphate-PNA on our cellular model. 
4.2.3. FLOW CYTOMETRIC ANALYSIS  
 
The ability of PNA7 S to recognize a specific DNA sequences was deter-
mined by analyzing its effect on the reduction of the amount of ErbB2 recep-
tor on cell surface of SKBR3 cells overexpressing ErbB2 by flow cytometric 
assays. In particular, SKBR3 were transfected with PNA7 S  in the presence 
of lipofectamine at different concentration of the compound. The cells, har-
vested after 48 h, were incubated in the presence of Herceptin as primary 
antibody.  The signal, indicating the binding of Herceptin to the receptor on 
SKBR3 cell surface, significantly decreases in the presence of increasing 
amount of PNA7 S. Differently, there was no signal change when cells were 
transfected with PNA in the same conditions. This experiment suggests that 
the PNA7 S, unlike PNA7, is able to inhibit the expression of the receptor in a 
dose-response manner (Figure 52).  
 
 
Figure52: Flow cytometric analysis of ErbB2 expression on SKBR3 cells. (A) Histo-
grams were obtained from at least three independent experiments. Data are expressed as 
percentage of decrease vs control (cells not transfected and treated with an anti-ErbB2 an-
tibody) ± SE. Statistical significance was carried out by means of the two tailed, paired, 
Student’s t test, **p<0.01, *p<0.05. (B)  Single result representative of three similar experi-
ments. Not transfected cells (black curve), not transfected and treated cells with an anti-ErbB2 an-
tibody (green curve), transfected with 10 mM PNA7 S and treated with an anti-ErbB2 antibody (red 
curve) and transfected with 10 mM PNA7 and treated with an anti-ErbB2 antibody (blue curve).  
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4.2.4. qPCR.  
 
A quantitative analysis of ErbB2 expression was obtained by qPCR. In de-
tail, SKBR3 cells were transfected for 48 h with different amounts of PNA7 S 
or PNA7 in the presence of lipofectamine and then total RNA was extracted 
from cells.  Following the reverse transcription, performed using random 
primers and MMLV reverse-transcriptase, a qPCR reaction was carried out 
using specific primers for glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH, a housekeeping gene, used as reference gene) and ErbB2.  
Data from this analysis showed that the PNA7 S was able to reproducibly 
down-regulate ErbB2 expression at all concentrations tested. The expression 
of ErbB2 in the presence of 10 M was significantly lower than that at 5 M 
(CT: 13.7 and 12.0, respectively). In contrast, treatment with PNA does not 
reduce ErbB2 gene expression (Table 8). 
 
                                   ErbB2                         GAPDH 
Antigene oli-
gonucleotides 
Threshold 
Cycle (CT) 
SD Threshold 
Cycle (CT) 
SD 
Control 11.5 0.00 11.9 0.08 
PNA S  5 M 12.0* 0.14 11.7 0.18 
PNA S  10 M 13.7** 0.09 11.8 0.05 
PNA 5 M 11.5 0.08 10.9 0.21 
PNA 10 M 11.0 0.16 10.4 0.19 
Table 8 : qPCR of ErbB2 and GAPDH genes. RNA was obtained after transfection of 
SKBR3 cells  with PNA S and PNA at 5 and 10 M concentration. The experiments were 
performed in triplicate and repeated at least 3 times. Data are expressed as medium CT ± 
SD. Statistical significance was carried out by means of Student’s t test, (* p= 0.02; **p= 
0.0006). 
 
qPCR and FACS analyses demonstrate that a treatment of SKBR3 cells 
with PNA S determines a significant decrease both in gene expression and in 
the amount of receptor on SKBR3 cell surface. These results suggest that 
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PNA7 S binds to the ErbB2 promoter, likely forming a triplex, and acts as an 
antigéne. One of the major challenges in the design of an antigéne molecule 
is the optimization of its DNA binding, which is achieved in several ways, for 
example conjugating to the PNA intercalating, chelating and alkylating 
agents, or using bis PNA65,141a, 151, 152.   
Interestingly PNA7 S forms triplexes less stable than the standard PNA, 
but it exhibits a biological  activity unlike PNA7. In this case it may be hy-
pothesized that the differences between PNA7 and PNA7 S are due to the dif-
ferent uptake of the two molecules: the negatively charged PNA7 S reasona-
bly binds strongly the cationic lipids used for the delivery, being able to 
reach the nucleus in a sufficient amount to determine the antigéne effect, 
unlike PNA7 which, lacking of charge, is not efficiently delivered to the nu-
cleus and therefore does not display any biological activity.  
Our hypothesis is consistent with results recently published, in which an 
efficient delivery, although measured on an antisense PNA7, was achieved 
attaching to the PNA7 a phosphonate or a bis phosphonate peptide153 and 
underlines how critical is  the efficiency in the uptake to achieve biological 
activity. 
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4.3. CONCLUSIONS 
 
PNA7 S is the first example reported so far of antigéne  PNA bearing a 
negative charge. The introduction of the sulphate group in the  position of 
the backbone positively influences the binding properties and the biological 
activity of the oligomer. The PNA7 S shows a strong binding selectivity to-
ward DNA, a potent antigéne activity and lack of toxicity.   
The ability to act as antigéne suggests how the biological activity of PNA 
based molecules strictly depends on their ability to be taken up by cells.  
sulphate PNAs represent  therefore a potent tool in strategies aimed at inter-
fering in gene expression.  
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4.4. MATERIALS AND METHODS 
 
Reagents for the synthesis and solvents were purchased at Sigma-Aldrich.  
Activators (HBTU and HOBt) and amino acids were purchased at Novabio-
chem. DIPEA, DMF, DCM were from Romil and piperidine from Biosolve. 
Fmoc-PAL-PEG-PS resin was from Applied Biosystems. Fmoc-T-OH and 
Fmoc-C(Bhoc)-OH PNA monomers were purchased at Link Technologies. 
Analytical RP-HPLC runs were carried out on a HP Agilent Series 1200 appa-
ratus using a Phenomenex Jupiter 5μ C18 300Å, 250x4.6 mm column with a 
flow rate of 1.0 mL min-1. LCMS analyses were run on a Thermo Finnigan in-
strument equipped with a MSQ ES source using a Phenomenex Jupiter 5μ 
C18 300Å , 150x4.6 mm column with a flow rate of 0.8 mL min-1. 
Preparative RP-HPLC was carried out on a Shimadzu 8A apparatus 
equipped with an UV Shimadzu detector using a Phenomenex Jupiter 10μ 
Proteo 90Å, 250x10 mm column. 
Circular dichroism spectra were recorded on a Jasco J-810 spectropo-
larimeter equipped with a Peltier thermal controller unity using a 1-cm 
quartz cell. 
Monodimensional 1H- and 13C-NMR spectra were recorded on a Varian 
Innova instrument (600 MHz) at room temperature. All chemical shifts are 
expressed in ppm with respect to the signals of the residual protonated sol-
vents (CDCl3 or DMSO-d6). Bidimensional NMR experiments were performed 
on a Varian UNITYINOVA 500 spectrometer, equipped with a 5-mm triple 
resonance probe and triple-axis pulsed-field gradients. 
 
 
 
 
118 
 
4.4.1.  Synthesis of the monomers 
 
 
 
 
Scheme 1: Synthesis of the backbone 
 
T A(Bz) C(Bz) G(iBu)
 
Scheme 2: Protected bases 
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Scheme 3: assembly of the monomers 
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B: B=A(Bz)
C: B=C(Bz)
D: B=G(iBu)
9) R = H, -Fmoc, A: B=T
B: B=A(Bz)
C: B=C(Bz)
D: B=G(iBu)
10) A: B=T
B: B=A(Bz)
C: B=C(Bz)
D: B=G(iBu)
11) A: B=T
B: B=A(Bz)
C: B=C(Bz)
D: B=G(iBu)
12) A: tS, B=T
B: aS, B=A(Bz)
C: cS, B=C(Bz)
D: gS, B=G(iBu)
4) B=T
5) B=A(Bz)
6) B=C(Bz)
7) B=G(iBu)
3
+
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Fmoc-Ser(tBu)-N(OCH3)CH3  (2a) 
Fmoc-Ser(tBu)-OH (1) (1.5 g, 3.9 mmol) was dissolved in dry CH2Cl2 (52 
mL). N,O-(dimethyl)-hydroxylamine chloridrate (0.507 mg, 5.2 mmol) and 
DMAP (47.8 mg, 0.39 mmol) were added and the mixture was cooled at 0°C. 
Triethylamine (933 μL, 0.678 g) and  EDC (0.9 g; 4.69 mmol) were added. 
The reaction was stirred 1 hour at 0°C and 19 hours at room temperature.  
 The crude was extracted with HCl 1N first, NaHCO3 aq. 10% and finally 
with H2O; the organic layer was treated with Na2SO4 an. , filtered and con-
centrated. The product was isolated after purification by silica gel chroma-
tography, eluted with ethylic ether /petroleum ether 1/1 v/v. 
Yield: 90% (1.66 g) 
Mass analysis: m/z (ESI), [M+H]+ calculated: 426.4 ; found: 426.5 
1H NMR(CDCl3): 1.16 ( 9 H, s, t-butyl-CH3), 3.24 (3H, s, -N-CH3-), 3.60-3.65 
(2H, m, -CH-CH2-O-), 3.77 (3H, s, -O-CH3), 4.23 (1H, t, Fmoc-CH-CH2-),  4.34 
(2H, d, Fmoc- CH2-O-), 4.87 (1H, t, -NH-CH-CH2- O-), 7.21-7.74 (8H, m, Fmoc) 
13C NMR (CDCl3): 27.34 (t-butyl-CH3-), 47.15 (-N-CH3), 51.80 (Fmoc-CH), 
61.48 (-NH-CH-C-), 62.04 (-O-CH3-), 67.10 (-CH2-O-Fmoc), 73.58 (t-butyl-C-), 
125.23, 125.21, 127.05, 127.66, 141.27, 143.87 (Fmoc), 144.00 (-CH2-COO-
N), 156.0 (-O-COO-NH). 
 
Fmoc-Ser(tBu)-OCH3  (3)  
Fmoc-Ser(tBu)N(OCH3)CH3 (2a) (0.78 g; 1.8 mmol) dissolved in dry di-
ethyl ether (11 mL) was cooled at 0°C under argon. Lithium aluminum hy-
dride (3.5 mL; 3.5mmol) was added dropwise and the reaction was stirred 
at  0°C, 1 hour.  The reaction was quenched with a solution of KHSO4 (0.2 M); 
the crude was extracted with H2O. The organic layer containing the aldehyde 
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Fmoc-Ser(tBu)-H (2b)  was treated with Na2SO4 an. , filtered and concen-
trated. 
Fmoc-Ser(tBu)-H(2b) (0.58 g; 1.5 mmol) dissolved in anhydrous CH3OH 
(16 mL) was cooled  at 0°C under nitrogen. In a separate flask glycine me-
thylester chlorhydrate (0.4 g;  3.1 mmol) was dissolved in CH3OH (2 mL) and 
DIPEA (500 L). The two solutions were mixed and the reaction was stirred 
at 4°C, 4hours . Acetic acid (290 L) and sodium cianoborhydride ( 152 mg; 
2.41 mmol) were then added and the mixture was stirred 30 minutes. The 
reaction was quenched with a solution of NaHCO3  10%; the crude was ex-
tracted with ethyl acetate. The organic layer was treated with Na2SO4 an. , fil-
tered and concentrated. Product 3 was purified by silica gel chromatography 
eluted in ethyl acetate/hexane7/3 v/v. 
Yield: 60 % (0.41g) 
Mass analysis: m/z (ESI), [M+H]+ calculated : 443.0 ; found :443.1 
1H NMR (CDCl3): 1.17 ( 9H, s, t-butyl-CH3), 2.11 (1H, s, -CH2- NH-CH2-), 2.74 
(2H, dd, -CH-CH2-N-), 3.44 (2H, bs, NH-CH2-COO), 3.47 (2H, br s, -CH-CH2-O-
), 3.70 (3H, s, -O-CH3), 3.88 (1H, br s, -NH-CH-CH2-), 4.23 (1H, m, Fmoc- CH-
CH2), 4.40 (2H, m, Fmoc-CH2-O), 7.28-7.76 (8H, m, Fmoc). 
13C NMR(CDCl3): 27.62 (t-butyl-CH3-), 47.42 (Fmoc-CH-CH2), 50.92 (-CH-
CH2-N-), 51.06 ( -NH-CH2-CO), 52.15 (-O-CH3), 62.25 (NH-CH-CH2-), 67.10 
(Fmoc-CH2-O-), 73.36 (CH-CH2-O-), 125.33, 127.25, 127.85 (Fmoc), 144.10, 
144.24 (Fmoc), 156.85 (-O-CO-N-) , 173.75 (COOCH3) 
 
Fmoc-Ser(tBu)-A(Bz)-OCH3 (8B) 
0.17 g of Fmoc-Ser(tBu)-OCH3 (3)(0.37 mmol) are dissolved in 3.7 mL of 
anhydrous DMF; A(Bz)-CH2COOH (224 mg, 0.75 mmol)(prepared following 
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the protocol reported by Finn, PJ et al.  Nucleic Acids Research (1996)) EDC 
(144.3mg, 0.75 mmol ) and DMAP (4.6 mg, 0.04 mmol) are added. After 12 
hours stirring the solvent is evaporated; the residue is dissolved in  CHCl3 
and washed with NaHCO3 aq. The organic layer is treated with Na2SO4 and the 
solvent evaporated. The product is purified by silica gel chromatography 
eluted in ethyl acetate/hexane 9/1 v/v. 
Yield: 85% (225 mg) 
Mass analysis: m/z (ESI), [M+H]+ calculated 698.0; found  698.2 
1H NMR(CDCl3): 1.26 (9H, s, t-butyl-CH3), 3.41–3.70 ( 4H, m, -CH–CH2–O-N-
CH-CH2), 3.72 (3H, s, OCH3), 3.82 (2H, s, CO-CH2-adenine), 3.97-4.20 (3H, m, 
NH-CH-CH2, NH-CH2-COOCH3), 4.28 (1H, t, CH-Fmoc), 4.40-4.41 (2H, d, CH2-
Fmoc), 7.28-7.75 (8H, m, Fmoc and  5H, m,  Bz), 8.12 (1H, s, H(2)-adenine), 
8.68 (1H, s, H, (8)-adenine). 
13C NMR (CDCl3): 27.90 (t-butyl-CH3), 44.22 (N-CH2-COO), 47.71 (Fmoc-CH-
), 49.26 (CH-CH2-N), 49.98 (-NH-CH-CH2), 52.84 (OCH3), 60.55 (-CO-CH2-
adenine), 67.20 (-Fmoc -CH2-), 67.43 (CH-CH2-O), 74.58 (t-butyl-C), 120.52 
(C(5)-adenine), 125.32, 127.55, 128.31, 129.34, 133.19, 134.30, 141.81, 
144.14 ( Fmoc), 144.64 (C(8)-adenine), 149.87 (C(4)-adenine), 153.17 
(C(2)-adenine), 155.00 (CO-Fmoc), 165.00 (CO-Bz), 169.83 (-CO-CH2-
adenine), 173.06 (COOCH3). 
Fmoc Ser(tBu)-A(Bz)-OH (10 B) 
224 mg of Fmoc-Ser(tBu)-A(Bz)-OCH3 (8B)(0.32 mmol) are dissolved in 
dioxane (4 mL) and treated with NaOH 2M ( 802 μL, 1.6mol). The mixture is 
stirred at r.t. and 0 °C, 2 hours;  HCl 1N is added until the pH of the solution 
is 5. The product is extracted with ethyl acetate and dried. The resulting 
NH2-Ser(tBu)-A(Bz)OH (156 mg, 0.32 mmol) is dissolved in 2.5 mL of 
H2O/CH3CN 1/1, FmocONSu (216.6 mg, 0.64 mmol) and NaHCO3 are added 
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(54 mg, 0.64 mmol). The reaction is carried out at pH=8, 2 hours. The reac-
tion is quenched with HCl 2M up to neutralization.  The crude is washed 
with CHCl3, the organic layer is dried. The product is purified by by silica gel 
chromatography eluted in ethyl acetate/methanol  9/1 v/v. 
Yield: 63% (143mg) 
Mass analysis: m/z (ESI), [M+H]+ calculated:  707.0; found:  707.2 
1H NMR (DMSO-d6): 1.21 (9H, s, t-butyl-CH3), 3.14-4.14 (7H, m, -CH-CH2-O, 
NH-CH-CH2, NH-CH-CH2, CO-CH2-adenine), 4.19-4.41 (5H, m, CH-Fmoc, CH2-
Fmoc, NH-CH2-COOH), 7.28-8.05 (8H, m, Fmoc and 5H, m, Bz), 8.30 (1H, s, 
H(2) adenine), 8.62 (1H, s, H(8) adenine). 
13C NMR (DMSO-d6): 31.02 (t-butyl-CH3), 47.90 (Fmoc-CH), 50.73 (COCH2-
adenine), 52.15 (NH-CH2-COOH), 53.36 (CH-CH2-N), 54.72 (NH-CH-CH2), 
69.00 (Fmoc-CH2-), 69.47 (CH-CH2-O), 76.82 (t-butyl-C), 124.09 (C(5)-
adenine), 129.17, 130.99, 131.59, 132.42, 136.36 , 144.71 ( Fmoc, Bz), 
137.41 (C(8)-adenine), 144.71 (C(4)-adenine), 149.50 (C(6)-adenine), 
153.90 (C(2)-adenine), 156.73 (COO-Fmoc), 169.64 (CO-Bz), 170.80 (CO-
CH2-adenine), 174.08 (COOH). 
 
Fmoc Ser(OH)-A(Bz)-OH (11B) 
Fmoc Ser(tBu)-A(Bz)-OH (10B) (143 mg) is suspended in TFA/DCM 1/1 
(3 mL); the solution is stirred 2 hours. The solvent is evaporated and the 
crude is lyophilized. Yield: 100% (131.5 mg) 
Mass analysis: m/z (ESI), [M+H]+ calculated :650.0; found:  650.3 
1H NMR: (DMSO-d6): 3.19 - 3.36 (2H, m, CH-CH2-N, rotamer B), 3.57-3.49 
(2H, m, CH-CH2-N, rotamer A), 3.60 (2H, m, CH-CH2-O, rotamer B), 3.70 (1H, 
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m, NH-CH-CH2 rotamer B), 3.72 (2H, m, CH-CH2-O, rotamer A), 3.88 (1H, m, 
NH-CH-CH2 rotamer A), 3.96-4.08 (2H, d, N-CH2-COOH), 4.24-4.34 (3H, m, 
CH-Fmoc, CH2-Fmoc), 5.20-5.26 (2H, d, CO-CH2-adenine, rotamer B),  5.42-
5.50 (2H, d, CO-CH2-adenine, rotamer A), 7.12 (1H, d, NH-CH-CH2 rotamer 
B), 7.25-8.10 (8H, m, Fmoc and  5H, m, Bz), 8.48 (1H, s, H(2)adenine), 8.68 
(1H, s, H(8)adenine). 7.41 (1H, d, NH-CH-CH2 rotamer A). 
13C NMR (DMSO-d6):  47.70 (CH-Fmoc), 50.00 (CO-CH2-adenine), 52.05 (NH-
CH2-CO), 53.20 (CH-CH2-N), 54.78 (NH-CH-CH2), 66.53 (CH-CH2-O), 69.40 
(CH2-Fmoc), 121.08 (C(5)-adenine), 132.42, 129.44, 128.59, 128.00, 126.16 
(Fmoc, Bz), 134.32 (C(8)-adenine), 144.79, 141.69 (Fmoc), 150.71 (C(4)-
adenine), 152.41 (C(6)-adenine), 153.62 (C(2)-adenine), 156.83 (CO-Fmoc), 
166.76 (CO-Bz), 167.71 (CO-CH2-adenine), 171.64 (COOH). 
 
Fmoc Ser(OSO3)-A(Bz)-OH (12 B) 
Fmoc Ser(OH)-A(Bz)-OH (11B) (143mg, 0.22mmol) is dissolved in 1.2mL 
of DMF and stirred under argon 10 minutes.  DMF·SO3 (134.8 mg, 0.88 
mmol) is added and the reaction is carried out 2 hours under argon at r.t.. 
The solvent is evaporated. Separately  a solution of NaHCO3 sat.(2.86mL) 
and  tetrabutylammonium bisulfate ( 154.4 mg) is prepared and cooled at 
0°C; this solution is added to the reaction mixture and  and reacted  under 
stirring 5 minutes. The pH of the solution is then adjusted to 5 with a 10% 
solution of citric acid. The crude is extracted 4 times with CHCl3, the organic 
layer is dried under vacuum. 
Yield: 95% 
Mass analysis: m/z (ESI), [M+H]+ calculated:  729.3; found:  729.4 
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1H NMR (DMSO-d6): 3.28 - 3.49 (2H, m, CH-CH2-N, rotamer B), 3.50-3.74 
(2H, m, CH-CH2-N, rotamer A), 3.73 (2H, m, CH-CH2-O, rotamer B), 3.86 (1H, 
m, NH-CH-CH2 rotamer B), 3.90 (2H, m, CH-CH2-O, rotamer A), 3.92-4.04 
(2H, d, N-CH2-COOH), 4.08 (1H, m, NH-CH-CH2 rotamer A), 4.24-4.34 (3H, m, 
CH-Fmoc, CH2-Fmoc), 5.11 (2H, sd, CO-CH2-adenine, rotamer B),  5.50-5.58 
(2H, d, CO-CH2-adenine, rotamer A), 7.28-8.10 (8H, m, Fmoc and 5H,m, Bz),  
7.35 (1H, d, NH-CH-CH2 rotamer B),7.62 (1H, d, NH-CH-CH2 rotamer A), 8.46 
(1H, bs, H(2)adenine), 8.66 (1H, bs, H(8)adenine). 
 
All other monomers are prepared following the same procedure de-
scribed for the adenine monomer.  Bases with the methylene carbonyl linker 
were prepared according to procedures described in the literature87, 140a. 
 
Fmoc-Ser(tBu)-T-OCH3   (8A) 
Yield: 89% (185.2 mg) 
Mass analysis: m/z (ESI), [M+H]+ calculated 609 ; found 609.2 
1H NMR (CDCl3): 1.21 (9H, s, t-butyl-CH3), 1.67-1.68 (3H, s, CH3-thymine), 
3.42-3.90 (4H, m, -CH-CH2-O-), 3.72 (3H, s, O-CH3), 3.79 (2H, dd, N-CH2-
COOCH3), 4.19-4.23 (1H, m, -NH-CH-CH2), 4.29 (1H, t, Fmoc-CH-CH2-), 4.41 
(2H, d, Fmoc-CH2-O-), 4.54-4.81 (2H, s, CO-CH2- thymine), 6.96-6.98 (1H, s, 
H(6)- thymine), 7.29-7.77 (8H, m, Fmoc), 8.02 (1H, s, NH- thymine), 8.24 
(1H, s, Fmoc-NH)  
13C NMR (CDCl3): 12.33 (CH3- thymine), 27.50 (t-butil-CH3), 47.27 (N-CH2-
CO), 47.56 (Fmoc-CH-CH2), 48.87 (CH-CH2-N), 49.60 (NH-CH-CH2-), 49.98 (-
CO-CH2- thymine), 52.35 (-O-CH3), 66.74 (Fmoc-CH2-O), 66.96 (-CH-CH2-O-), 
73.94 (t-butyl-C), 110.5 (C(5)- thymine), 125.00, 127.09, 127.80, 140.92, 
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141.18, 143.76 (Fmoc), 141.18 (C(6)- thymine), 150.75 (C(2)- thymine), 
163.83 (C(4)- thymine), 167.75 (-CO-CH2- thymine), 169.51 (COOCH3). 
 
Fmoc Ser(tBu)-T-OH  (10 A) 
Yield: 63% (223 mg) 
Mass analysis: m/z (ESI), [M+H]+ calculated:  595.0; found:  595.2 
1H NMR (DMSO-d6): 1.21 (9H, s, t-butyl-CH3), 1.67-1.68 (3H, s, CH3- 
thymine), 3.45-3.80 (4H, m,-CH-CH2-O, NH-CH-CH2), 3.82-3.98 (2H, s, NH-
CH2-COOH), 4.21-4.45 (5H, m, CH-Fmoc, CH2-Fmoc, CO-CH2- thymine), 7.21 
(1H, s, H(6)- thymine), 7.29-7.72 (8H, m, Fmoc). 
13C NMR (CDCl3): 11.48 (CH3- thymine), 26.75 (t-butyl-CH3), 46.27 (N-CH2-
COOH), 47.24 (CH-Fmoc), 48.09 (CH-CH2-N), 49.67 (NH-CH-CH2-), 50.21 
(CO-CH2- thymine), 65.00 (Fmoc-CH2-O), 71.98 (CH-CH2-O), 75.73 (t-butyl-
C), 107.56 (C(5)- thymine), 124.77, 126.59, 127.20, 141.62, 143.32 (Fmoc), 
140.23 (C(6)- thymine), 150.54 (C(2)- thymine), 163.93 (C(4)- thymine), 
167.75 (-CO-CH2- thymine), 170.54 (COOH). 
 
Fmoc Ser(OH)-T-OH  (11 A) 
Yield: 86% (174mg) 
Mass analysis: m/z (ESI), [M+H]+ calculated: 538.0 ; found: 538.2 
1H NMR (DMSO-d6): 1.67 (3H, s, CH3-thymine), 3.13 -3.34 (2H, m, CH-CH2-N, 
rotamer B),  3.33 -3.49 (2H, m, CH-CH2-N, rotamer A), 3.56 (2H, m, CH-CH2-
O, rotamer B), 3.57 (2H, m, CH-CH2-O, rotamer A), 3.67 (1H, m, NH-CH-CH2 
rotamer B), 3.78 (1H, m, NH-CH-CH2 rotamer A), 3.92-3.99 (2H, d, N-CH2-
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COOH),  4.21-4.40 (3H, m, CH-Fmoc, CH2-Fmoc) , 4.65-4.73 (2H, d, CO-CH2-
thymine), 7.10 (1H, d, NH-CH-CH2 rotamer B),7.26 (1H, bs, H(6)-thymine), 
7.29-7.90 (8H, m, Fmoc), 7.31 (1H, d, NH-CH-CH2 rotamer A) 
13C NMR (DMSO-d6): 15.91 (CH3-C5), 50.77 (CH-Fmoc), 51.79 (CO-CH2-
thymine), 53.24 (NH-CH2-COOH), 55.55 (NH-CH-CH2), 55.89 (CH-CH2-N), 
66.77 (CH2-Fmoc), 69.22 (CH-CH2-O-), 112.13 (C(5)- thymine), 124.15, 
129.26, 131.10, 131.67 (Fmoc), 144.76, 147.88 (Cq Fmoc), 146.07 (C(6)- 
thymine), 155.01 (C(2)- thymine), 159.98 (COO-Fmoc), 168.43 (C(4)- 
thymine), 171.55 (CO-CH2- thymine), 174.28 (COOH) 
 
Fmoc Ser(OSO3)-T-OH (12 A) 
Mass analysis: m/z (ESI), [M+H]+ calculated: 617.0 ; found: 618.0 
1H NMR (DMSO-d6): 1.69 (3H, s, CH3-thymine), 3.32-3.47 (2H, m, CH-CH2-N, 
rotamer B),  3.40  - 3.58 (2H, m, CH-CH2-N, rotamer A), 3.55 (2H, m, CH-CH2-
O, rotamer B), 3.77 (1H, m, NH-CH-CH2 rotamer B), 3.94-3.96 (2H, d, N-CH2-
COOH),  3.97 (2H, m, CH-CH2-O, rotamer A), 4.08 (1H, m, NH-CH-CH2 ro-
tamer A), 4.18-4.32 (3H, m, CH-Fmoc, CH2-Fmoc) , 4.45 (2H, d, CO-CH2-
thymine, rotamer B) , 4.65-4.73 (2H, d, CO-CH2-thymine, rotamer A), 7.26-
7.90 (8H, m, Fmoc), 7.31 (1H, bs, H(6)-thymine), 7.33 (1H, d, NH-CH-CH2 ro-
tamer B), 7.52 (1H, d, NH-CH-CH2 rotamer A). 
 
Fmoc Ser(tBu)-C(Bz)-OCH3  (8C) 
Mass analysis: m/z (ESI),  [M+H]+ calculated: 698.0 ; found: 698.2  
1H NMR (CDCl3): 1.22 (9H, s, t-butyl-CH3), 3.30-3.40 (2H, m, CH-CH2-O), 
3.45-3.54 (2H, m, CH-CH2-O), 3.71 (3H, s, OCH3), 3.78 (2H, s, CO-CH2-
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cytosine), 3.95-4.65 (7H, m, NH-CH-CH2, CH-Fmoc, CH2-Fmoc, N-CH2-
COOCH3, H(5)-cytosine), 7.38 (1H, d, H(6)-cytosine), 7.38-7.90 (8H,m, Fmoc 
and 5H,m, Bz). 
13C NMR (CDCl3): 47.75 (Fmoc-CH), 49.37 (N-CH2-CO), 50.03 (CH-CH2-N), 
50.42 (NH-CH-CH2), 52.79 (CO-CH2-cytosine), 67.18 (CH2-Fmoc), 67.46 (CH-
CH2-O), 73.94 (t-butyl, Cq), 97.11 (C(5)-cytosine), 125.63, 127.58, 127.75, 
128.12, 128.23, 129.17, 129.47 (Fmoc, Bz), 133.61(Cq-Bz), 141.77, 144.26 
(Cq-Fmoc), 144.98 (C(6)-cytosine), 150.95 (C(2)-cytosine), 156.75 (COO-
Fmoc), 163.18 (CO-CH2-cytosine), 168.05 (COO-Bz), 170.09 (COO-OCH3). 
 
Fmoc Ser(tBu)-C(Bz)-OH (10 C)   
Yield: 80% (130 mg) 
Mass analysis: m/z (ESI),  [M+H]+ calculated : 684.0; found :684.2 
1H NMR (DMSO-d6): 1.21 (9H, s, t-butyl-CH3), 3.20-4.15 (7H, m, -CH-CH2-O, 
NH-CH-CH2, NH-CH-CH2, CO-CH2-cytosine), 4.21-4.40 (6H, m, CH-Fmoc, CH2-
Fmoc, NH-CH2-COOH, H(5)cytosine), 7.38 (1H, d,H(6)-cytosine), 7.38-8.05 
(8H, m, Fmoc, 5H, m, Bz). 
13C NMR (DMSO-d6): 31.22 (t-butyl-CH3), 50.73 (CH-Fmoc), 52.07 (CO-CH2-
cytosine), 53.65 (NH-CH2-COOH), 54.23 (NH-CH-CH2), 54.90 (NH-CH2-CH), 
69.45 (CH2-Fmoc), 69.59 (CH-CH2-O), 76.47 (t-butil-C), 99.72 (C(5)-
cytosine), 129.23, 131.05, 131.61, 132.43 (Fmoc, Bz), 136.67 (Cq-Bz), 147.30, 
147.83 (Cq-Fmoc), 147.90 (C(6)-cytosine), 155.08 (C(2)-cytosine), 159.08 
(COO-Fmoc), 159.91 (C(4)-cytosine), 167.34 (COO-CH2-cytosine), 171.31 
(COO-Bz), 174.27 (COOH). 
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Fmoc Ser(OH)-C(Bz)-OH (11 C)   
Mass analysis: m/z (ESI), [M+H]+ calculated: 628.0 ; found:  628.1 
1H NMR (DMSO-d6): 3.18  - 3.36 (2H, m, CH-CH2-N, rotamer B),  3.38 -3.52 
(2H, m, CH-CH2-N, rotamer A), 3.56 (2H, m, CH-CH2-O, rotamer B), 3.61 (2H, 
m, CH-CH2-O, rotamer A), 3.67 (1H, m, NH-CH-CH2 rotamer B), 3.79 (1H, m, 
NH-CH-CH2 rotamer A),3.88-4.08 (2H, d, N-CH2-COOH), 4.18-4.35 (3H, m, 
CH-Fmoc, CH2-Fmoc), 4.67 (2H, bs, CO-CH2-cytosine, rotamer B), 4.88-4.94 
(2H, d, CO-CH2-cytosine, rotamer A), 6.05 (1H, d, H(5)cytosine), 7.10 (1H, d, 
NH-CH-CH2 rotamer B), 7.23-8.05 (8H, m, Fmoc and  5H, m, Bz), 7.31 (1H, d, 
NH-CH-CH2 rotamer A ), 7.80 (1H, d,H(6)-cytosine) 
13C NMR (DMSO): 50.70 (CH-Fmoc), 51.75 (CO-CH2-citosina), 53.68 (NH-
CH2-COOH), 55.49 (NH-CH-CH2), 55.96 (CH-CH2-N), 66.77 (CH-CH2-O), 69.53 
(CH2-Fmoc), 99.74 (C(5)-citosina), 129.21, 131.06, 131.60, 132.42 (Fmoc, 
Bz), 136.67 (Cq, Bz), 144.71, 147.85 (Cq Fmoc), 147.90 (C(6)-cytosine), 
155.07 (C(2)-cytosine), 159.02 (CO-Fmoc), 162.06 (C(4)-cytosine), 167.01 
(CO-CH2-cytosine), 171.31 (COO-Bz), 174.22 (COOH). 
 
Fmoc Ser(OSO3)-C(Bz)-OH (12 C)   
Yield: 91% 
Mass analysis: m/z (ESI), [M+H]+ calculated ;706.7; found : 706.7 
1H NMR (DMSO-d6): 3.30 - 3.49 (2H, m, CH-CH2-N, rotamer B), 3.42 – 3.63 
(2H, m, CH-CH2-N, rotamer A),  3.74 (2H, m, CH-CH2-O, rotamer B), 3.83 (2H, 
m, CH-CH2-O, rotamer A), 3.86 (1H, m, NH-CH-CH2 rotamer B), 3.88-4.05 
(2H, d, N-CH2-COOH), 4.00 (1H, m, NH-CH-CH2 rotamer A), 4.28 (3H, m, CH-
Fmoc, CH2-Fmoc), 4.74- 4.67 (2H, d, CO-CH2-cytosine, rotamer B), 4.82 - 5.02 
(2H, d, CO-CH2-cytosine, rotamer A), 6.10 (1H, d, H(5)cytosine), 7.25-8.02 
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(8H, m, Fmoc and 5H, m, Bz), 7.32 (1H, d, NH-CH-CH2 rotamer B),7.56 (1H, d, 
NH-CH-CH2 rotamer A), 7.80 (1H, d,H(6)-cytosine) 
FmocSer(tBu)-G(iBu)-OCH3 (8 D) 
Yield: 67% (366 mg) 
Mass analysis: m/z (ESI), [M+H]+ calculated: 704.9 ; found: 705.0 
1H NMR (CDCl3): 1.14 (6H, d, CH3-isobutiryl), 1.17 (9H, s, t-butyl-CH3), 2.55-
2.75 (1H, m, -CH-(CH3)2), 3.10-3.32 (2H, m, CH-CH2-O), 3.40- 3.58 (2H, m, -
CH-CH2-N), 3.69 (3H, s, OCH2), 3.79 (CO-CH2-guanine), 4.18-4.30 (1H, m, NH-
CH-CH2), 4.38 (1H, m, CH-Fmoc), 4.70-4.80 ( m, 5H, CH2-Fmoc, N-CH2-COO-
OCH3, CH-Fmoc), 7.24-7.74 (1H, s, CH-guanine). 
13C NMR (CDCl3): 19.28 (CH3-isobutiryl), 27.95 (CH3-t-butyl), 36.44 (CH-
(CH3)2-isobutiryl), 47.50 (CH-Fmoc), 47.83 (N-CH2-CO), 48.55 (CH-CH2-N), 
50.01 (NH-CH-CH2), 52.78 (OCH3), 67.35 (CH2-Fmoc), 74.24 (C-t-butyl), 
120.53 (C(5)-guanine), 125.33,127.25, 127.84 (Fmoc), 140.28 (C(8)-
guanina), 141.78, 144.00 (Cq Fmoc), 148.40 (C(2)-guanine), 148.80 (C(8)-
guanine), 149.22 (C(4)-guanine), 156.26 (CO-Fmoc), 157.13 (C(6)-guanine), 
167.62 (CO-CH2-guanine), 170.05 (COOCH3), 179.80 (CO-isobutiryl). 
 
Fmoc Ser(tBu)-G(iBu)-OH (10 D) 
Yield: 81% (290 mg) 
Mass analysis: m/z (ESI), [M+H]+ calculated : 690.8 ; found: 690.9 
1H NMR (DMSO-d6): 1.13 (6H, d, CH3-isobutiryl), 1.19 (9H, s, t-butyl-CH3), 
2.72-2.80 (1H, m, CH-(CH3)2), 3.10-3.50 (5H, m, CH-CH2-O, CH-CH2-N, NH-
CH-CH2), 4.08 (2H, s, CO-CH2-guanine), 4.27- 4.28 (5H, m, CH-Fmoc, CH2-
Fmoc, N-CH2-CO), 7.33-7.87 (8H, m, Fmoc), 7.92 (1H, d, H(8)-guanine). 
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13C NMR  (DMSO-d6): 22.75 (CH3-isobutiryl), 31.20 (CH3-t-butyl), 38.69 (CH-
(CH3)2-isobutiryl), 47.99 (CH-Fmoc ), 50.72 (CO-CH2-guanine), 52.05 (NH-
CH2-CO), 54.32 (CH-CH2-N), 55.11 (NH-CH-CH2), 69.37 (CH2-Fmoc), 69.53 
(CH-CH2-O), 76.49 (CO-t-butyl), 124.127 (C(6)-guanine), 129.08, 129.17, 
131.00, 131.68 (Fmoc), 144.73, 147.75 (Cq-Fmoc), 147.89 (C(8)-guanine), 
151.86 (C(2)-guanine), 153.22 (C(4)-guanine), 158.85 (CO-Fmoc), 159.83 
(CO-C(6)-guanine), 171.32 (CO-CH2-guanine), 174.72 (COOH), 184 (CO-
isobutiryl). 
 
Fmoc Ser(OH)-G(iBu)-OH  (11 D) 
Yield : 100% 
Mass analysis: m/z (ESI), [M+H]+ calculated: 634.9 ; found: 635.2 
1H NMR (DMSO-d6): 1.08 (6H, d, CH3-isobutiryl), 2.70 (3H, m, CH-(CH3)2, 
CH2- CH-(CH3)2),  3.16 - 3.33 (2H, m, CH-CH2-N, rotamer B), 3.37- 3.49 (2H, 
m, CH-CH2-N, rotamer A), 3.57 (2H, m, CH-CH2-O, rotamer B), 3.67 (2H, m, 
CH-CH2-O, rotamer A), 3.67 (1H, m, NH-CH-CH2, rotamer B),  3.90 (1H, m, 
NH-CH-CH2, rotamer A), 3.98-4.07 (2H, d, N-CH2-COOH), 4.20- 4.33 (3H, m, 
CH-Fmoc, CH2-Fmoc), 4.95 (2H, bs, CO-CH2-guanine, rotamer B),  5.12-5.21 
(2H, d, CO-CH2-guanine, rotamer A), 7.12 (1H, d, NH-CH-CH2 rotamer B), 
7.24-7.90 (8H, m, Fmoc), 7.43 (1H, d, NH-CH-CH2 rotamer A) , 7.89 (1H, d, 
H(8)-guanine)  
13C NMR (DMSO): 22.89 ( CH3- isobutiryl), 38.70 (CH-(CH3)2- isobutiryl), 
47.99 (CH-Fmoc), 50.69 (CO-CH2-guanine), 52.02 (NH-CH2-COOH), 53.55 
(CH-CH2-N), 56.06 (NH-CH-CH2), 69.59 (CH2-Fmoc), 70.35 (CH-CH2-O), 
123.30 (C(5)-guanine), 129.14, 131.03, 131.63 (Fmoc), 144.72 (Cq-Fmoc), 
147.81 (C(8)-guanine), 151.95 (C(2)-guanine), 153.22 (C(4)-guanine), 
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158.76 (CO-Fmoc), 162.42 (CO-C(6)-guanine), 170.73 (CO-CH2-guanine), 
174.26 (CH-CH2-COOH), 184.06 (CO- isobutiryl). 
 
Fmoc Ser(OSO3)-G(iBu)-OH  (12 D) 
Yield : 100% 
Mass analysis: m/z (ESI), [M+H]+ calculated: 714.9 ; found : 713.9 
1H NMR (DMSO-d6): 1.08 (6H, d, CH3-isobutiryl), 2.74 (3H, m, CH-(CH3)2, 
CH2- CH-(CH3)2),  3.21 -3.47 (2H, m, CH-CH2-N, rotamer B), 3.39 -3.69 (2H, m, 
CH-CH2-N, rotamer A),3.71 (2H, m, CH-CH2-O, rotamer B), 3.85 (1H, m, NH-
CH-CH2, rotamer B),3.87 (2H, m, CH-CH2-O, rotamer A), 3.96-4.02 (2H, d, N-
CH2-COOH), 4.04 (1H, m, NH-CH-CH2, rotamer A),  4.22- 4.33 (3H, m, CH-
Fmoc, CH2-Fmoc), 4.95 (2H, d, CO-CH2-guanine, rotamer B),5.14-5.22 (2H, d, 
CO-CH2-guanine, rotamer A), 7.25-7.89 (8H, m, Fmoc), 7.32 (1H, d, NH-CH-
CH2 rotamer B), 7.53 (1H, d, NH-CH-CH2 rotamer A), 7.92 (1H, d, H(8)-
guanine) . 
 
4.4.2. Solid phase conditions for coupling of PNA7 S monomers 
Fmoc Ser(OSO3)-T-OH: 50 µL of a 0.3M solution  ( 7.9 eq.) in an. DMF of 
monomer, 50 µL of HBTU (0.2M) (5.2 eq.) in DMF, 50 µL MDCH (0.8M) in 
pyridine, 30 minutes. 
Fmoc Ser(OSO3)-C (Bz)-OH, Fmoc Ser(OSO3)-A (Bz)-OH, Fmoc Ser(OSO3)-G 
(iBu)-OH: 50 µL  of a 0.3M solution  ( 7.9 eq.) in an. DMF of monomer, 50 µL  
of HBTU (0.2M) (5.2 eq.) in DMF, NMM 0.2M, 50 µL  of pyridine 0.2M in DMF 
, 30 minutes. 
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4.4.3. Solid phase synthesis of PNA7 , PNA7 S and PNA7 OH 
 
Oligomers were obtained by solid phase synthesis on  the Fmoc-PAL-PEG-
PS resin (0.19 mmol/g) using a  2 µmol scale. The synthesis is carried out by 
repetitive cycles of deprotection, coupling and capping. 
Deprotection: 20% piperidine in DMF, 7 minutes 
Capping: Acetic anhydride 5%, 2,6 lutidine 6%  in DMF,  5 minutes. 
Coupling for PNA7 S and PNA7 OH:  
Fmoc-C(Bhoc)-OH: 50 µL of a monomer 0.2M solution in an. DMF (5 eq.), 50 
µL of HATU 0.18M in DMF (4 eq.), and 50 µL of  DIPEA(0.2 M)/ 2,6 lutidine 
(0.3M) in DMF  30 minutes. 
Fmoc Ser(OSO3)-(T)OH (12 A) and Fmoc Ser(OtBu)-(T)OH (10 A): 50 µL of a 
monomer 0.3M solution  ( 7.9 eq.) in an. DMF, 50 µL of HBTU (0.2M) (5.2 
eq.) in DMF, 50 µL MDCH (0.8M) in pyridine, 30 minutes. Modified mono-
mers are always double coupled.  
Coupling for PNA 7: the protocol described in chapter 2 followed.  
At the end of the synthesis the oligomer is cleaved off the resin and depro-
tected by treatment with TFA/m-cresol 80/20, 90 min. , r.t.. The TFA is con-
centrated and the PNA is precipitated with cold diethyl ether. The sample is 
lyophilized and purified by RP-HPLC using a gradient of acetonitrile (0.1% 
TFA) in H2O (0.1% TFA) from 5 to 25% in 30 minutes. 
ESI analysis for PNA7 S: calculated: [M+H]+= 2694.44 m/z ; [M + 2H]2+ = 
1348.2 m/z, [M + 3H]3+= 899.1 m/z 
found: [M + 2H]2+ = 1346.35 m/z, [M + 3H]3+ = 897.15 m/z 
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ESI analysis for PNA7: calculated: [M+H]+= 2323.26 m/z; [M + 2H]2+ = 
1162.63 m/z; [M + 3H]3+ = 775.42 m/z 
found: [M + 2H]2+ = 1163.9 m/z; [M + 3H]3+ = 775.96 m/z 
 
ESI analysis for PNA7 OH: calculated: [M+H]+= 2415.44 m/z; [M + 2H]2+ = 
1208.22 m/z; [M + 3H]3+ = 805.74;  ; [M + 4H]4+= 604.61 m/z; ;  [M + 5H]5+= 
483.88 
found: [M + 3H]3+ = 804.28 m/z; [M + 4H]4+ = 603.20 m/z;  [M + 5H]5+= 
483.90 
 
4.4.4. NMR spectroscopy  
The 2D spectra were acquired using the TPPI (time-proportional phase-
incrementation) method to obtain complex data points in the t1 dimension. 
A standard set of 2D experiments DQF-COSY,26 TOCSY27 and NOESY25 were 
acquired at 25°C142a. The TOCSY experiments were recorded using a 
MLEV17 mixing scheme of 70 ms with 9 kHz spin-lock field strength; the 
NOESY spectra were carried out with a mixing time of 150 ms. Chemical 
shifts were referenced to external TMS (tetramethylsylane) (=0 ppm). For 
data processing and spectral analysis the programs VNMR 6.1B and CARA 
were used (Bartels C et al 1995). All samples were purified by HPLC before 
analysis. 
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4.4.5. Determination of the stoichiometry of the complex by Job Plot 
 
Concentrations of the single strands was determined by UV at 260nm, using 
for S-PNA and PNA  = 64.5 Lmol-1cm-1 and for DNA   = 101.6 Lmol-1cm-1.   
3 M solutions of  PNA7 S, PNA7 and DNAc  in Phosphate buffer 10mM, 
100mM NaCl, pH = 7 were prepared. Solutions at different molar fraction of 
PNA7 S (or PNA7) and DNAc were prepared, keeping constant the (PNA7 S 
or PNA 7 + DNA) total concentrations . 
 Samples were annealed, warming up at 90°C and slowly cooling down to 
4°C. UV spectra were recorded on a Jasco spectrophotometer at 25°C. Plot-
ting the molar fraction (X) of PNA7 S or PNA7 vs the Absorbance at 260nm,  
a minimum around 0.7 X PNA7 is found, which indicates the stoichiometry 
of the complexes is (PNA7 S and PNA) 2: DNAc 1. The experiment was per-
formed in duplicate. 
 
4.4.6. CD analyses 
CD spectra were recorded at 5°C in the 320-200 nm range and are the re-
sults of 6 scans. Single strands and triplexes were dissolved in Phosphate 
buffer 10mM, 100mM NaCl, 5mM MgCl2  pH = 7. Triplexes were annealed by 
warming up at 90°C and slowly cooling down to 4°C. 
Thermic denaturation experiments were carried out using  3 M triplexes 
at a 0.5°C/min scan speed, recording  at  225 nm for PNA7 S and PNA7 and 
at 266 nm for DNA triplexes. 
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4.4.7. Biological Assays  
 
Cell culture.  
SKBR3 cells (ATCC, U.S.) were grown in DMEM supplemented with 10% 
fetal bovin serum (FBS), 1% glutamine, 100 U/mL penicillin and 100 µg/mL 
streptomycin (Invitrogen, U.S.), at 37 °C and 5% CO2.  
 
Citotoxicity assay.  
For the evaluation of the cytotoxic effect of compounds, the exponentially 
growing cells were seeded at a density of 5.0 x103/well in 96-well flat bot-
tom tissue culture microplates, and incubated with 1, 5 and 10 M of PNA7 S 
at 37°C for 72 hours. Cell number was evaluated with crystal violet, which 
correlates optical density with cell number, according to the procedure de-
scribed by Gilles et al.  
 
SKBR3 Binding Assay by Fluorescence Activated Cell Sorting (FACS).  
7.5x104 cells/well were plated in 24-well plates, allowed to adhere for 24 h, 
and then transfected using Lipofectamine LTX (Invitrogen, CA, U.S.) accord-
ing to the manufacturer's instruction, with PNA7 S or PNA7. After 48 h, cells 
were incubated with 10 nM Herceptin (kindly provided by Dr. S. De Luca , 
IBB, CNR Italy), then washed with PBS 1X, 0.1% BSA and incubated with a 
1:1000 dilution of primary antibody (mouse anti-human, clone HP6017, 
SIGMA, U.S.). Secondary antibody (goat anti-mouse FITC-conjugate, Santa 
Cruz, CA, U.S.) was used at 1:200 dilution. Subsequently cells were detached, 
resuspended in PBS 1X, 0.1% BSA and analyzed by flow cytometer, equipped 
with a 488 nm argon laser (FACScalibur Becton Dickinson, U.S.).  
For each sample 20.000 events were acquired and analyzed using Cell 
Quest software. 
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RT-PCR and qPCR.  
Total RNA was extracted from lysates of transfected cells by using Tri-
reagentTM (Sigma Aldrich, U.S.) according to the manufacturer’s instructions. 
Reverse transcription was performed using 0.5 µg of total RNA, 200 U of 
MMLV (Finnzymes, Finland) and 250 ng of random primers (Fermentas, 
Germany). Reaction temperature was set at 42 °C for 1 h. The reaction buffer 
was: 50 mM Tris HCl pH 8.3; 75 mM KCl; 3 mM MgCl2; 5 mM DTT.  
After reverse transcription, qPCR assay was carried out using the follow-
ing primers, GAPDH: forward primer, 5’-ATGGGGAAGGTGAAGGTC-3’, re-
verse primer 5’-GTCATGGATGACCTTGGC-3’ (purchased by Sigma-Genosys 
Ltd); ErbB2: forward primer, 5’-GGGAAGAATGGGGTCGTCAAA-3’, reverse 
primer 5’-CTCCTCCCTGGGGTGTCAAGT-3’.  
The amplification reactions were run at least in triplicate. Reactions were 
performed in Rotor-gene Q (Qiagen) and contained 2 μL cDNA, 3 μL of prim-
ers (final primer concentration of 10 M each), and 10 μL of SYBR Premix Ex 
Taq II (Takara, Japan), in a final volume of 25 μL. The qPCR protocol was as 
follows: 2 minutes at 95 °C followed by 45 cycles of 1 minute at 95 °C, 1 min 
at 60 °C and 1 min at 72 °C.  
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